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Advances in sequencing technology have greatly reduced the costs incurred in 
collecting raw sequencing data and researchers now have access to very large datasets of 
genomic alterations. Computational tools are necessary in order to interpret and discover 
biologically relevant genetic variation from sequencing data. Current computational 
tools, however, have overwhelmingly focused on single nucleotide changes. Much less 
work has been devoted to computational tools to prioritize insertion and deletion variants 
and chromosomal abnormalities. Insertion/deletion variants (indels) alter protein 
sequence and length, yet are highly prevalent in healthy populations, presenting a 
pressing need for bioinformatics classifiers. Chromosomal abnormalities can produce a 
wide range of genetic disorders including in miscarriages, developmental disorders, and 
carcinogenesis. While numerous tools have been developed to detect chromosomal 
abnormalities, these tools have limited utility at lower cell admixtures. 
In this dissertation, I focus on the development of computational approaches 
beyond single nucleotide variants. I introduce a novel computational approach to assess 
indels variants (Chapters 2-3). I compare this method to existing computational 
approaches and investigate potential ways to improve indel prediction. Next, I develop a 
bioinformatics approach entitled WALDO (Within-sample AneupLoidy DiscOvery) 
specifically designed to detect chromosomal abnormalities as well as microsatellite 
instability (Chapters 4-6). 
Thesis Advisor: Rachel Karchin 
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Chapter 1: Overview 
With the advent of high-throughput sequencing technology, researchers face a 
bottleneck in terms of the time required to analyze the potential impact on disease 
etiology of the many genetic variants routinely detected. Computational algorithms can in 
principle help researchers to prioritize and direct future work by narrowing down the 
numerous genetic alterations identified in sequencing studies. Current tools have largely 
focused on single nucleotide changes and much less work on insertion/deletion (indel) 
variants and chromosomal abnormalities. 
1.1 Computational Methods to Prioritize Single Nucleotide 
Changes 
1.1.1 Non-Synonymous Single Nucleotide Variants 
Non-synonymous single nucleotide variants are genetic variants that alter the 
protein sequence. Experimental assessment of protein activity for mutated proteins is 
very difficult, and is further impeded by the large number of NS-SNVs revealed by 
exome sequencing studies. This has motivated the development of many statistical and 
computational methods for evaluating the functional impact of non-synonymous changes 
on proteins. The methods fall broadly into two categories, those that score mutations on 
the basis of biological principles (SIFT 1, MutationAssessor 2, MAPP 3, PANTHER 4, 
among others), and methods that use existing knowledge about the functional effects of 
mutations in the form a training set for supervised machine learning (PolyPhen2 5, SNAP 
6, SNPs3D 7, MutPred 8, MutationTaster 9, among others 10). These methods are known to 
perform well at distinguishing Mendelian disease mutations from common single 
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nucleotide polymorphisms 9 and usually offer either a numeric score that represents the 
predicted functional impact of an amino acid substitution, or a probability that the 
substitution is deleterious to the protein. Mutation scores can be used to substantially 
reduce the number of candidate disease-causing mutations detected in exome sequencing 
studies, but additional evidence is still needed to identify the causal mutation  
1.1.2 Single Nucleotide Splice Variants 
 
Ample evidence indicates sequence changes at key regions in pre-mRNA may 
cause aberrant splicing resulting in disease 11; 12, and single nucleotide variants (SNVs) at 
splice sites are known to contribute to at least 10% of identified inherited diseases 12. 
Importantly, SNVs beyond the splice site can also cause disease by disrupting the binding 
of splicing machinery and occur in both exons and introns. Current estimates suggest as 
much as 25% of known Mendelian disease exonic SNVs thought to impair protein 
function through missense and nonsense changes actually disrupt splicing 13; 14. There is 
also evidence that SNVs deep into the intron (further than 50 bp from the exon/intron 
boundary) can even cause aberrant splicing 15. Numerous computational methods can 
predict the impact of splice site SNVs but only a few attempt to identify which additional 
exonic and intronic SNVs are important for splicing 16-19.  
Computational prediction of SNVs at exon/intron junctions is based on strong 
signals of consensus di-nucleotide conservation, whereas prediction outside of the 
immediate vicinity of exon/intron junctions will require integration of many complex 
weaker cis-acting signals 20. One of these weaker signals is the positional distribution of 
sequence motifs. Methods for hierarchical clustering of motifs have been developed to 
identify higher-level patterns of organization 14; 21. Beyond positional distribution, the 
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complex network of weaker signals depends on conservation 22 and RNA secondary 
structure 23.   
1.2 Insertion and Deletion Variants 
Inherited (germline) and non-inherited (somatic) insertion/deletion variants 
(referred to as indels throughout) in both the coding and noncoding region of the genome 
play a critical role in human health. The average human exome contains over four 
hundred naturally occurring germline micro- indels24.  In-frame indels account for ~50% 
of these variants, and result from the insertion/deletion of an integer number of codons, 
and ultimately amino acids.  Frameshifts account for the other ~50% of indels, and result 
from contiguous nucleotide insertions/deletions of a length not divisible by three.  This 
fractional change in the number of codons shifts the translational reading frame, resulting 
in an entirely new downstream sequence thereby shifting the position at which the first 
stop codon is encountered. Thus, frameshift indels translate to protein that is very distinct 
from the native protein, particularly if the indel occurs early in the transcript sequence.  
Both in-frame and frameshift indels alter protein sequence and length.  
Because they drastically alter protein primary structure, but are also highly 
prevalent in healthy populations, indels present a unique classification challenge.  
Clearly, the principles governing pathogenicity are not identical to those governing 
changes in protein function and stability; otherwise, most indels would be pathogenic.  
The challenge then arises because protein sequence, structure, function and stability are 
typically considered when assessing a variant of unknown impact on disease liability 25.  
These protein-based criteria could lead to a high false positive rate, and therefore low 
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specificity, because the fraction of indels that appreciably impact health might be 
overestimated.  
Additionally, somatic indels in both the coding and non-coding region play a key 
role in cancer. Somatic indels that disrupt DNA repeats indicate a sample has impaired or 
deficient DNA mismatch repair (MMR) that results in microsatellite instability (MSI). 
Detection of MSI has a drastic impact on cancer treatment and survivability 26. The 
traditional way to detect MSI uses a panel of just 5 markers 27. Next generation 
sequencing techniques can analyze a much larger number of locations but analyzing 
repetitive regions can be computationally challenging 28. 
The increased utilization of high-throughput genomic sequencing technologies 
and hopes for their clinical application, coupled with the high prevalence of indels, has 
led to a demand for bioinformatic tools connected to indel variants.   
1.3 Chromosomal Abnormalities (Aneuploidy) 
Aneuploidy is an abnormal number of chromosomes resulting from chromosomes 
not properly splitting during cell division 29 and can produce a wide range of genetic 
disorders ranging from spontaneous abortions, Down syndrome (Trisomy 21), Patau 
syndrome, (Trisomy 13), Edwards syndrome (Trisomy 18), Turner syndrome (XO), 
Klinefelter syndrome (XXY), Triple X syndrome 29 as well as carcinogenesis 30-32. There 
is a pressing need for prenatal and cancer screening computational techniques to reliably 
detect micro-deletions, duplications as well as whole chromosome gains and losses.  
Many aneuploidy detection protocols are invasive procedures such as 
amniocentesis, chorionic villus, and biopsy. Invasive procedures have a non-negligible 
risk of fetal loss 33 and can cause severe pain and complications 34.  Genetic screening 
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using cell free DNA has many advantages over invasive techniques.  Circulating cell free 
DNA can be retrieved from blood, urine, and stool 35and can include fetal DNA 
(cffDNA) 36 or tumor DNA (ctDNA) 37. Genetic screening from fetal or tumor cell free 
DNA, however, can be challenging due to extremely low admixtures rates from the 
source of interest. Fetal DNA fraction typically 12% depending on the stage of pregnancy 
38 39; 40 and tumor DNA fraction can range from less to .01% to well over 10 % depending 
on the stage and type of tumor 41.  
Most available methods use either whole genome or exome sequencing which 
require library preparation. Library preparation includes several sequential steps: 1) end-
repair, 2) 5′-phosphorlyation; 3) addition of a terminal dA nucleotide to the 3′ ends of the 
fragments, 4) ligation of the fragments to adapters, 5) and polymerase chain reaction 
(PCR) amplification of the ligated products. Following PCR amplifications, the products 
are then quantified and sequenced. The reads are aligned and analyzed. Whole genome 
and exome sequencing have well documented biases resulting from GC content, DNA 
fragment size, quality, 42 and capture efficiency 43; 44.  
This process can be simplified by sequencing long interspersed nuclear elements 
(LINEs). LINEs are non long terminal repeat retrotransposons that comprise 20% of the 
human genome and are present on every chromosome 45. Because LINEs are highly 
repetitive, a discrete set of positions can be amplified from a single primer pair 
eliminating the need for end-repair, terminal 3′-dA addition, and ligation to adapters 
during library preparation. Reads can then be used to identify key types of structural and 
sequence variation important in human health. Using a predefined, discrete set of 
positions also has the potential to reduce alignment time, streamline the analysis 
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workflow, and achieve the necessary coverage at lower costs—all obstacles limiting the 
widespread use of whole genome and exome sequencing in genetic testing. 
Numerous methods have been developed to identify structural changes from 
whole genome and exome sequencing reads (reviewed in 46) but few have been 
developed specifically for lower admixtures rates typically observed from cell free DNA 
(reviewed in 47). Most cell free DNA methods were designed for prenatal testing with 
much less work on cell free tumor DNA (reviewed in 48 48). Cancer screening can be 
much more challenging than prenatal testing due to the larger numbers of gains and 
losses observed across many different chromosomes 48.   
My thesis work develops novel computation approaches to interpret 
insertion/deletion variants and detect aneuploidy and MSI using LINE sequencing.   
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Chapter 2: Variant Effect Scoring Tool for 
Insertions and Deletions (VEST-indel) 
Insertion/deletion variants (indels) alter protein sequence and length, yet are 
highly prevalent in healthy populations, presenting a challenge to bioinformatics 
classifiers.  Commonly used features—DNA and protein sequence conservation, indel 
length, and occurrence in repeat regions—are useful for inference of protein damage.  
However, these features can cause false positives when predicting the impact of indels on 
disease. Existing methods for indel classification suffer from low specificities, severely 
limiting clinical utility.  Here, I further develop the Variant Effect Scoring Tool (VEST) 
to include the classification of in-frame and frameshift indels (VEST-indel) as pathogenic 
or benign.   
2.1 History of Computational Assessment of Insertion and 
Deletion Variants 
Most computational methods for assessing genetic variation initially focused on 
missense variants; more recently, several groups have extended these methods to handle 
indels 49-53.  Most of these methods utilize supervised machine learning classifiers and are 
trained on two classes of indel:  pathogenic from disease mutation databases and benign 
from either population variation databases or tolerated interspecies variations derived 
from genomic alignments. DDIG-in is based on a support vector machine, and the 
authors of this method reported a sensitivity of 0.86 and specificity of 0.72 for frameshift 
indels 53, and a sensitivity of 0.89 for in-frame indels 50; the authors did not report 
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prediction specificity for in-frame indels. PROVEAN uses an unsupervised approach that 
compares the reference protein sequence with a sequence that incorporates a variant of 
interest 49.  The authors of PROVEAN reported high sensitivities of 0.93 and 0.96 for in-
frame insertions and deletions, respectively, and a specificity of 0.80 for in-frame 
insertions and 0.68 for in-frame deletions; PROVEAN does not assess frameshift indels. 
SIFT-indel, based on a J48 Decision Tree 54 , achieved good balanced accuracies for in-
frame (sensitivity=0.81; specificity=0.82) 52 and frameshift indels (sensitivity=0.90; 
specificity=0.78) 51.  However, the neutral dataset used in those studies comprised indels 
derived from cross-species comparisons.  As the authors state, SIFT-indel was trained to 
predict impact on gene function, irrespective of impact on disease.  Indeed, when the 
method was applied to variants from human variation databases, the majority of the 
indels were predicted to be deleterious; thus, specificities would be below 50% for 
predicting indel pathogenicity.  The CADD classifier utilized a unique approach, in 
which a support vector machine was trained to discriminate fixed (or nearly fixed) 
derived alleles in humans from a set of simulated variants 55. The CADD classifier was 
developed to predict deleterious variants rather than variant pathogenicity or impact on 
protein function, but with the stated assumption that these quantities are all related.  The 
authors of CADD reported classifier performance on missense variants and indels 




2.2.1 Data Collection  
A curated set of in-frame and frameshift indels (micro-deletions and micro-
insertions) of ≤20 base-pairs in length, annotated as being pathogenic from publications 
in the biomedical literature, was downloaded from Human Gene Mutation Database 56 
(2014v.3).  Only high-confidence annotations with the "DM" designation were included.  
A second curated set of in-frame and frameshift indels was downloaded from the NCBI 
ClinVar database on August 7, 2014. Only entries annotated as ‘likely pathogenic’ 
(Clinical Significance 4) or ‘pathogenic’ (Clinical Significance 5) and not annotated as a 
somatic mutation were included. Any entry from ClinVar that was also present in HGMD 
was removed from the ClinVar set.  Annotated in-frame and frameshift variants were 
downloaded from the Exome Variant Server using (ESP6500SI-V2-SSA137) 57 [Fu, et 
al., 2013] and from the 1000 Genomes Project Phase 3 (ftp://ftp-
trace.ncbi.nih.gov/1000genomes/ftp/) 58. To increase the likelihood that variants from the 
Exome Variant Server and 1000 Genomes Project were benign common polymorphisms, 
and to retain sufficient variants for the training set, I only used variants with a minor 
allele frequency (MAF) ≥ 0.01 and occurring in either African individuals or those of 
African ancestry.  In ESP600, these were identified as "African-American" and in 1000G 
as the AFR superpopulation comprising YRI (Yoruba in Ibadan, Nigeria), LWK (luhya in 
Webuye, Kenya), GWD (Gambian in Western Divisions in the Gambia), MSL (Mende in 
Sierra Leone), ESN (Esan in Nigeria), ASW (Americans of African ancestry in SW 
USA), and ACG (African Caribbeans in Barbados). The other populations represented in 
ESP6500 and 1000G are believed to have experienced severe bottlenecks in recent 
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history, and hence individuals from these populations may harbor potentially pathogenic 
variants at higher MAF than individuals of African ancestry 51; 59-61. A curated set of 
putatively benign in-frame and frameshift indels, derived from pairwise genome 
alignments of human and cow, dog, horse, chimpanzee, rhesus macaque and rat, was 
generously provided to us by Pauline Ng and Jing Hu.  This set had been previously used 
to train their SIFT-indel classifier 51; 52. Additional background information about these 
data sets, including probability densities for indel length and MAF, are shown in Figure 
S 1. 
The number of variants used for this study, grouped by source and ontology, were: 2,523 
in-frame deletions, 565 in-frame insertions, 17,606 frameshift deletions, and 8,265 
frameshift insertions from HGMD 2014.3; 43 in-frame deletions, 14 in-frame insertions, 
344 frameshift deletions, and 134 frameshift insertions from HGMD 2014.4; 1,991 in-
frame deletions, 404 in-frame insertions, 774 frameshift deletions, and 618 frameshift 
insertions from ESP6500; 86 in-frame deletions, 70 in-frame insertions, 37 frameshift 
deletions, and 23 frameshift insertions from 1000 Genomes, Phase 1; 304 in-frame 
deletions, 261 in-frame insertions, 229 frameshift deletions, and 134 frameshift insertions 
from 1000 Genomes, Phase 3; 16 in-frame deletions, 5 in-frame insertions, 32 frameshift 
deletions, and 74 frameshift insertions from ClinVar; 4,686 in-frame deletions, 3,406 in-
frame insertions, 706 frameshift deletions, and 628 frameshift insertions from the above-
mentioned genome alignments.  
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2.2.2 Feature Selection 
The Random Forest Feature Importance Z-score 62 was used to rank a set of 49 
candidate features from 63 and 5 additional features (Table S 1), using PARF software 
(http://code.google.com/p/parf), with 100 trees and default parameters.  To avoid 
overfitting, an independent feature-selection set was used (500 pathogenic and 500 
benign examples for each of the in-frame and the frameshift classifiers). I used a greedy 
algorithm to identify a good, minimum set of features. Briefly, beginning with the top-
ranked feature, a Random Forest was trained using only that feature and 10-fold cross-
validation was used to estimate the classifier's area under the ROC curve (AUC). I 
successively added the next top-ranked feature until all candidate features were included. 
For the in-frame classifier, the maximum AUC was achieved with 23 features and for the 
out-of-frame classifier, the maximum AUC was achieved with 16 features (Table S 2).  
These features were used for the remainder of the work described here. The selected 
features include measures of gene importance, the damaging effect of the variant on 
protein activity, evolutionary conservation and protein local environment (Table S 3). 
2.2.4 Classifier Training Protocol 
Random Forest classifiers were trained to classify in-frame and frameshift 
variants (using PARF software with 100 trees and default parameters).  For in-frame 
classifier training, 2,475 pathogenic and 1,877 benign examples were available, whilst 
24,478 pathogenic and 1,350 benign examples were available for frameshift classifier 
training (Table 1). To handle class imbalance, the in-frame classifier was trained on a 
randomly selected set of 1,877 pathogenic examples and all 1,877 benign examples.  Ten 
frameshift classifiers were trained on a randomly selected set of 1,350 pathogenic 
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examples and all 1,350 benign examples (repeated 10 times, sampling without 
replacement).  All ten classifiers were used to score frameshift variants, by computing ten 
scores for each variant and averaging them. 
  
 13 













In-frame           
Pathogenic 500a 2475a 39b N/A 57f 
Benign 500c 1877c 8105d 346e 156e 
Frameshift 
    
 Pathogenic 500a 24478a 184b N/A 478f 
Benign 500c 1350c 1340d 537e 60e 
 
Superscript letters indicate the source of the examples for each type of insertion/deletion 
variant and each stage of VEST-indel development (feature selection, classifier training, 
classifier validation, empirical null)  aHGMD, bClinVar, cESP6500, dInter-species 
benigns from SIFT-indel, e1000G Phase 3, and fHGMD2014. There is no overlap 
between examples in any of the columns.  N/A = not applicable because only benign 




2.2.5 Statistical Framework 
I developed an analytical null score distribution based on Random Forest 
classifier scores of putative benign variants (1000 Genomes Project Phase 3, MAF ≥0.01, 
African ancestry). The scored variants (537 for in-frame insertion/deletions, 346 for 
frameshift insertion/deletions) did not overlap the examples used for Random Forest 
feature selection, training or the independent test set.  An empirical cumulative 
distribution (ECDF) of scores was calculated and modeled as a Generalized Pareto 
Distribution (GPD) (Equation 1)64; 65.  
Equation 1 
 
where k and a are the GPD shape and scale parameters, respectively (in-frame k=0, a=-



























Chapter 3: VEST-indel Performance Evaluation 
In protein-coding exons, in-frame indels generally have a less severe impact than 
frameshifts 61.  Since the biological effect of in-frame and frameshift indels is different, I 
chose to develop two distinct Random Forest classifiers to handle these two distinct 
variant types.  Performance of the classifiers was assessed in three phases: 1) I estimated 
sensitivity and specificity with stringent, homology-restricted ten-fold cross-validation 
(pathogenic class from HGMDv2014.3 56, benign from ESP6500 African Ancestry 57) 
(Table 2); 2) I re-estimated sensitivity and specificity on an independent test set of 
variants (pathogenic class from ClinVar 66, benign Interspecies alignments 51; 52) (Table 
2) that had not been used in classifier training and had been filtered for homology overlap 
with the cross-validation set; 3) I re-estimated sensitivity and specificity on a second 
independent test set of variants (pathogenic class from new entries in HGMDv2014.4, 
benign from 1000 Genomes Phase III African Ancestry 24 that did not overlap with any 
training data used by previously published methods (multi-method benchmark set); 4) I 
tested all possible meta-predictors that can be obtained from combining the four different 
indel classifiers using Boolean conjunctions and disjunctions. Finally, I sought to use 
VEST-indel scores to perform combine prioritization of different types of genetic 
variation (missense, in-frame, and frameshift variants).  
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Table 2: Training and Validation Sets Used by Current Prediction Methods  
 
1000G P1 and 1000G P3 are variants from 1000 Genomes Phase 1 and 3, respectively. Interspecies benign variants 
derived from pairwise genome alignments of human and cow, dog, horse, chimp, rhesus macaque, and rat. Uniprot 
variants were obtained from the UniProtKB/Swiss-Prot “Human Polymorphisms and Disease Mutations” dataset 
(Release 2011_09), annotated as deleterious, neutral, or unknown based on keywords from the provided Uniprot 




3.1 Homology Restricted Cross Validation 
The in-frame indel Random Forest and each of the ten frameshift Random Forests 
were assessed for sensitivity, specificity and balanced accuracy, using a rigorous ten-fold 
cross-validation protocol. The same protocol was applied to the missense Random Forest 
to assess combined prioritization of all three mutation types. To avoid overestimating 
performance, I ensured that any examples from genes whose protein products had ≥ 35% 
sequence identity were included in the same fold. BlastP with default parameters 67 was 
used for pairwise alignment of protein sequences and sequence identity calculations 67.  
Evidence suggests that homology-restricted cross-validation is important to avoid overly-
optimistic estimates of pathogenicity classifier performance 68. In the cross-validation 
experiments, VEST-indel achieved a sensitivity and specificity of 0.90 for in-frame 
indels (Table 3). Cross-validation performance for frameshift indels was slightly lower, 
with a sensitivity of 0.83, specificity of 0.88, and balanced accuracy of 0.85.   
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Table 3: VEST-indel Performance Metrics. 
 
  Sensitivity Specificity 
Balanced 
accuracy 
In-frame Cross Validation  0.90 0.90 0.90 
In-frame Testing 0.80 0.85 0.82 
Frameshift Cross 
Validation 
0.83 0.88 0.85 
Frameshift Testing 0.89 0.86 0.87 
 
Training utilized 10-fold cross validation and pathogenic variants from Human Gene 
Mutation Database 2014.3 and benign examples from Exome Sequencing Project (minor 
allele frequency in African Ancestry ≥ 0.01). The test set consisted of pathogenic 
examples from ClinVar and benign examples derived from pairwise genome alignments 
of human and cow, dog, horse, chimp, rhesus macaque, and rat.  
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3.2 Independent Test Set 
An independent set of examples, having no overlap with feature selection, 
training or empirical null sets, was constructed.  I removed any test set examples whose 
protein products had ≥ 35% sequence identity with any training examples 67. Pathogenic 
in-frame and frameshift mutations were taken from ClinVar 66 and benign in-frame and 
frameshift variants were taken from the interspecies set. All data were ‘cleaned’ so as to 
ensure that there was no overlap between these examples and the other three data sets.  
3.3 Comparison of insertion/deletion variant pathogenicity 
predictors 
3.3.1 Multi-Method Benchmark Set  
Four previously published methods were selected for comparison with VEST-
indel.  Three of the methods (SIFT-indel, DDIG-in, CADD) 49-53  handle both in-frame 
and frameshift insertion/deletions and the fourth method PROVEAN 49 handles only in-
frame variants. To perform an unbiased comparison of VEST-indel and the four other 
methods, I identified a set of 553 pathogenic and 357 benign examples, which did not 
overlap with any examples used to train, fit parameters, select features, or validate 
performance by any of the four methods. This multi-method benchmark set comprised 
pathogenic examples (61 in-frame and 491 frameshift) from the most recent version of 
HGMD (2014v.4), excluding any examples present in earlier versions of HGMD that had 
been used to train DDIG-in, SIFT-indel, or VEST-indel (PROVEAN and CADD were 
not trained on HGMD).  Benign examples (224 in-frame and 118 frameshift) were taken 
from 1000G Phase 3 (MAF ≥0.10, African Ancestry).  Any examples present in 1000G 
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Phase 1 or ESP6500, which were used to train or validate any of PROVEAN, DDIG-in, 
CADD or VEST-indel were omitted. Only examples for which every method returned a 
prediction result were included. The final multi-method benchmark set comprised 59 
benign frameshift insertion/deletion and 163 benign in-frame insertion/deletion variants 
(MAF≥0.1 from 1000G AFR super-population), as well as 474 pathogenic frameshift and 
53 pathogenic in-frame variants from HGMD v.2014.4 
(http://karchinlab.org/vest_indel_additional_files/Additional_File_2.xlsx).   
3.3.2 Method Usage  
SIFT-indel and DDIG-in provide a categorical classification for each example 
(Damaging/Neutral or Disease/Neutral) and a confidence measure. PROVEAN, CADD 
and VEST-indel provide a numerical score for each example (-40 to 12.5, 1 to 99, 0 to 1).  
To compare methods, PROVEAN scores were assigned to categories of Damaging (<-
2.5) or Neutral (≥-2.5) (as recommended by the authors) and VEST-indel scores were 
assigned to categories of Pathogenic (≥0.5) or Benign (<0.5), which represents a majority 
vote of decision trees in the Random Forest classifier. CADD scaled "C-scores" were 
assigned to categories of Deleterious (<15) or not Deleterious (≥15) (as recommended on 
their webserver). Sensitivity (TP/(TP+FN)), specificity (TN/(TN+FP)) and balanced 
accuracy ((sensitivity+specificity)/2) were calculated for each method, where TP = the 
number correctly classified as pathogenic (or damaging or disease) examples, FN = the 
number of incorrectly classified pathogenic examples, TN = the number of correctly 
classified benign (or neutral) examples, and FP = the number of incorrectly classified 
benign examples.  
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3.3.3 Indel Classifier Performance 
Table 4 compares performance achieved by the five methods for classifying 
neutral and disease-causing indels from the multi-method benchmark set.  VEST-indel 
shows superior specificity for classifying both in-frame (0.96) and frameshift (0.95) 
indels.  These high specificities further validate the ability of VEST-indel to accurately 
reject neutral variants as disease causing. All methods had reasonably high balanced 
accuracies for in-frame indel classification, with VEST-indel and PROVEAN yielding 
the highest balanced accuracy of 0.88.  Of note, VEST-indel and PROVEAN achieved 
nearly identical balanced accuracies with approximately equal trade-offs in sensitivity 
and specificity (Table 3).  For frameshift variants, VEST-indel outperformed the other 
methods, having a balanced accuracy of 0.90, compared with 0.77 for DDIG-in, 0.59 for 
SIFT-indel, and 0.52 for CADD. In the case of DDIG-in, VEST-indel showed 
substantially improved sensitivity and specificity (Table 4). The dramatic gain in 
performance achieved by VEST-indel, relative to SIFT-indel and CADD, resulted from a 
marked gain in specificity (0.95 vs. 0.25 for SIFT, and 0.05 for CADD); this is consistent 
with previous reports for SIFT-indel, which maintains good specificity when predicting 
protein-damaging indels, but suffers low specificity when predicting pathogenicity }51; 52.  
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Table 4: Comparing performance with previously published results and testing all 
methods with the new multi-method benchmark dataset. 
  
   Previously published 
 
Multi-method benchmark 
Sensitivity  Specificity Sensitivity Specificity 
Balanced 
Accuracy 
In-frame     
 
      
VEST-
indel 
0.90† 0.90†  
 
0.81  0.96 0.88 
SIFT-indel 0.81 0.82 
 
0.86 0.76 0.81 
DDIG-in 0.89 N/A 
 
0.78 0.91 0.84 
PROVEAN 0.93/0.96 0.80/0.68 
 
0.95 0.80 0.88 
CADD N/A N/A 
 
0.74 0.88 0.81 
Frameshift     
 





0.85 0.95 0.90 
SIFT-indel 0.90 0.78 
 
0.94 0.25 0.59 
DDIG-in 0.86 0.72 
 
0.75 0.80 0.77 
CADD N/A N/A 
 
0.98 0.05 0.52 
 
Previously published sensitivity and specificity based on author's cross-validation 
experiments. PROVEAN does not use cross validation so the reported numbers are from 
validation set experiments done separately for insertion and deletion variants. N/A = not 
applicable. Published results for the DDIG-in in-frame classifier do not include 
specificity; their self-reporting consists of an accuracy (not balanced accuracy) of 0.84 
and precision of 0.81. The authors of CADD did not report the performance achieved 
with indels separately. †Results from Table 1included here for comparison. Multi-
method benchmark set consisted of pathogenic examples from Human Gene Mutation 
Database 2014.4 and benign examples 1000 Genomes Phase 3 (minor allele frequency in 
African Ancestry ≥ 0.1).  
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3.4 Boolean Meta-predictors 
In these Boolean expressions, each method is represented by a variable Xi, which 
is set to TRUE when the method classifies an example as pathogenic and FALSE when 
the method classifies an example as benign. For combinations of two methods, candidate 
meta-predictors were  and . For combinations of three 
methods, candidate meta-predictors , ,
, , , 
, , , 
. For combinations of four methods, there are 64 possible 
combinations (Table S 4).  I used a brute-force approach and limited the number of 
methods in the meta-predictor to a maximum of four to avoid a combinatorial explosion.  
All possible four-way combinations of the five methods were explored.  
Although VEST-indel, SIFT-indel, DDIG-in, PROVEAN and CADD share some 
similarities with respect to training sets and features, I considered that they might be 
different enough to provide independent information about an indel of interest.  
Therefore, they could be combined into a meta-predictor to yield improved performance.  
This approach has had some success in predicting the pathogenicity of missense variants 
69-71.  Using the multi-method benchmark set, I assessed the classification performance 
resulting from each pair, trio, or quartet of methods combined using Boolean 
conjunctions and disjunctions.  See Supp. Table S6-7 for a complete list of the tested 
combinations.    
(X1  AND X2 ) (X1  OR X2 )
(X1  AND X2  AND X3) (X1  OR X2  OR X3)
(X1  OR X2  OR X3) ((X1  AND X2 ) OR X3) ((X1  OR X2 ) AND X3)
((X1  AND X3) OR X2 ) ((X1  OR X3) AND X2 ) ((X2  AND X3) OR X1)
((X2  OR X3) AND X1)
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For in-frame classification, the combination of ((VEST-indel AND PROVEAN) 
OR (CADD AND DDIG-in)) yielded a substantially improved sensitivity (0.93) while 
retaining good specificity (0.97), when compared to VEST-indel alone (sensitivity=0.81, 
specificity=0.96), and indeed any of the methods alone (Table S 6). This result indicates 
that these methods are highly complementary when combined in the described fashion.  
Conversely, for frameshift classification, the combination of ((VEST-indel AND (SIFT-
indel OR DDIG-in)) had roughly equivalent sensitivity (0.83) and specificity (0.97) to 
VEST-indel alone (sensitivity=0.85, specificity=0.95).  This results because the most 
specific method (VEST-indel) is combined using the AND operation (i.e., sensitivity 
could not possibly increase, nor could specificity decrease).  
The strategy of classifying a variant as pathogenic if any of the classifiers 
predicted it to be pathogenic (i.e., combining classifiers with a Boolean OR) did not yield 
good results.  For the in-frame classifier, the combination (VEST-indel OR SIFT-indel 
OR PROVEAN OR CADD) had a sensitivity of 1 but a specificity of 0.56, with balanced 
accuracy of 0.78.  Combining four classifiers or three classifiers with the OR operator 
consistently yielded good sensitivity but a substantial decrease in specificity.  This result 
is, to some extent, expected because combining classifiers with the OR operation 
increases the possibility of accepting a variant as pathogenic.  Conversely, requiring that 
all classifiers agree (i.e., combining classifiers with a Boolean AND) reduces the 
probability of a pathogenic classification.  Indeed, all meta-predictors that used only 
AND operators had high specificity, but low sensitivity.  For example, the (VEST-indel 
AND SIFT-indel AND CADD AND DDIG-in) meta-predictor had a specificity of 1.00 
and sensitivity of 0.46.  Taken together, these results highlight the benefit of developing 
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meta-predictors that combine Boolean conjunctions and disjunctions, rather than 
considering only a single type of Boolean operation.  
3.5 Combined Prioritization of Indel and Missense Variants 
For each in-frame, frameshift or missense variant, a VEST score was computed 
using homology-restricted 10-fold cross-validation with the appropriate Random Forest 
(Performance Assessment). Then a p-value was calculated using the analytical null 
(Equation 1) for its respective type.   To assess whether VEST could correctly prioritize 
a pathogenic variant over a benign variant, irrespective of whether the variant was in-
frame, frameshift or missense, I ranked the combined set of variants according to p-value, 
and computed area under the Receiving Operator Characteristic (ROC) curve 72.  
To compare VEST results with CADD, which also provides combined 
prioritization, I scored the same variants using the CADD.  Variants were ranked 
according to their scaled C-scores and area under the ROC curve was computed.  
VEST-indel p-values for in-frame and frameshift indels are comparable to VEST 
p-values for missense variants and as a result, multiple variant types can be jointly 
prioritized.   I assessed joint prioritization performance by combining variants from the 
VEST-indel in-frame and frameshift training sets (Table 1) and variants from the VEST 
missense training set 73 (2475 pathogenic and 1877 benign in-frame indels; 24478 
pathogenic and 1350 benign frameshift indels; 38221 pathogenic and 38221 benign 
missense variants) (Figure 1).  I also assessed performance in a balanced set, in which I 
randomly selected 1350 pathogenic and 1350 benign variants of each type for the 
combined set.  VEST p-values and scaled CADD scores were used to compute ROC area 
under the curve (AUC).   For the combined set, VEST and CADD achieved a similar 
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ROC area under the curve (AUC) of 0.90 and 0.88, respectively.  For the balanced set, 
VEST classification resulted in an AUC of 0.91 and CADD classification resulted in an 





Figure 1: Combined Prioritization results comparing VEST and CADD.  
A) VEST 3.0 ROC Curve on the variant test set dominated by missense variants B) 
CADD ROC Curve on the test set dominated by missense variants C) VEST 3.0 ROC 
Curve on the variant test set where by missense and indels have equal proportions D) 






3.6.1 Selective pressures on genes and false positive classifications 
A standard method for identifying genes under selection is Tajima's D statistic74, 
and for each gene harboring a variant in the multi-method benchmark set, I computed this 
statistic based on its longest annotated RefSeq transcript 75.  If RefSeq transcripts were 
not available for the gene, the longest annotated Ensembl transcript 76 [Cunningham, et 
al., 2015] was used. These calculations were performed using SNPs in 1000 Genomes 
Phase 3 AFR samples and the PopGenome package in R 77 [Pfeifer, et al., 2014].  Each 
gene was assessed for the presence of statistically significant positive or balancing 
selection (p<0.05).  The PopGenome package estimates P-values by simulation using 
Hudson's coalescent model [Hudson, 2002]. The benign examples in the multi-method 
benchmark set were taken from the 1000 Genomes Phase 3 samples, limited to 
individuals in the AFR (African) super-population 24 and having MAF≥0.1.  Whereas 
common variants are generally considered to be non-pathogenic 78, datasets of common 
variants may be contaminated by pathogenic variants if they occur in genes that are not 
under purifying selection 51.  I assessed the possibility that the multi-method benchmark 
set might include common pathogenic variants.  If this were the case, a false positive call 
from one of the methods might represent the correct identification of a truly pathogenic 
variant.  Genes not subject to purifying selection might alternatively be under positive, 
balancing, or relaxed (neutral) selection 51.  For each of VEST-indel, SIFT-indel, DDIG-
in, PROVEAN, and CADD I assessed the relationship between variants under selective 
pressure and those called as false positives, using Fisher's exact test (two-tailed, α=0.05).  
None of the benign variants were under balancing selection, defined as a statistically 
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significant (nominal p<0.05) positive Tajima's D statistic. Thirteen frameshift and 56 in-
frame variants were under positive selection, defined as a statistically significant 
(nominal p<0.05) negative Tajima's D statistic.  With the exception of a borderline p-
value for DDIG-in in-frame variant classification (p=0.051), there were no statistically 
significant relationships between positively selected variants and variants that were called 
as false positives.  For frameshift variants, p=1.0 for VEST-indel, p=0.26 for SIFT-indel, 
p=0.18 for DDIG-in, and p=0.40 for CADD.  For in-frame variants, p=0.25 for VEST-
indel, p=0.56 for SIFT-indel, p=0.13 for PROVEAN, and p=0.79 for CADD.   
3.6.2 Conclusion 
In this study, I sought to develop a method for predicting indel pathogenicity.  
This functionality is distinct from existing classifiers that were developed to predict indel 
impact on protein structure or function.  Although clinical utility appears to be a common 
goal for much of bioinformatics methods development, indel pathogenicity prediction 
presents the challenge of distinguishing variants that affect protein structure and function 
from those that adversely affect health 24.  Given the enrichment for protein sequence and 
annotation features available for algorithmic development 79; 80, the difficulty 
discriminating neutral and disease-causing indels might be unsurprising.  The newly 
developed classifier, VEST-indel, partially addresses previous methodological 
limitations, and achieves high balanced accuracy even when tasked with sorting disease-
associated indels from those present in the general population.  In particular, VEST-indel 
realized substantial gains in specificity relative to existing methods, highlighting 
reductions in falsely classifying neutral variants as pathogenic.  To realize these 
performance gains, VEST-indel heavily utilized a new feature that captures the known 
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relevance of a gene to human health.  This new “PubMed” feature leverages decades of 
community-wide biomedical research.  Thus, the algorithm uses features that ultimately 
estimate indel impact on protein, and the PubMed feature additionally estimates the 
biological context of the protein.  Given that poor specificity also limits the utility of 
methods aimed at assessing the pathogenicity of missense variants 81-84, the approach 
presented here might prove beneficial for variant classification in general.  
The in-frame meta-predictor ((VEST-indel OR DDIG-in) AND (PROVEAN)) 
achieved excellent sensitivity (0.93) and specificity (0.94) when applied to the multi-
method benchmark dataset.  This complementarity results because the two high-
specificity classifiers are combined using the OR operation, which is then combined with 
the high-sensitivity classifier PROVEAN, using the AND operation (see individual 
classifier performance, Table 4).  The Boolean OR operation increases the possibility of 
pathogenic classification; importantly, pathogenic classification from VEST-indel and 
DDIG-in is complementary rather than entirely overlapping, hence the increased 
sensitivity relative to either method alone.  As expected, however, the specificity of the 
(VEST-indel OR DDIG-in) classifier decreased (see Table S 6).  Next, even though the 
highly sensitive PROVEAN is slightly more prone to false positives, the specificity of the 
meta-predictor cannot decrease owing to the unanimity required by the AND operation; 
on the contrary, the complementarity of true-negative calls among these three classifiers 
restores a high specificity.  This is deliberate in the explanation because meta-predictor 
derivation relying on a single Boolean operation type is limiting and can result in 
significant trade-offs in sensitivity and specificity.  As the results show, taking advantage 
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of the complementarity that can result from combining Boolean conjunctions and 
disjunctions can be beneficial when maximizing balanced accuracy is desired. 
The new VEST-indel method can be used in combination with VEST scoring of 
missense variants to yield a jointly prioritized list of both variant types.  This analysis 
requires a single batch submission to the CRAVAT server 85. To my knowledge, the only 
other automated method available for such joint ranking is CADD.  For data sets in which 
the number of missense variants far exceeds the number of indels, VEST and CADD 
have similar performance.  However, when variant types (indels and missense) and 
classes (pathogenic vs. benign) are evenly distributed, VEST significantly outperforms 
CADD.   
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Chapter 4: Aneuploidy Detection  
 
Over 100 years ago, Theodor Boveri demonstrated sea urchins require the proper 
number of chromosomes for embryonic development 30. He also noted the role of 
abnormal number of chromosomes in cancer 30. Developing techniques to accurately 
detect aneuploidy is important for both prenatal screening and cancer detection. 
4.1 Prenatal Screening 
Approximately 1 of 154 live births have a major chromosomal abnormality 86. 
This rate increases with the inclusion of still-born or miscarriage pregnancies 87. Some of 
the most common chromosomal abnormalities include Trisomy 21 (Down syndrome) 1 in 
831 live births, Triple X 1 in 909, XYY 1 in 969, XXY 1 in 969, Trisomy 18 (Edward’s 
Syndrome) 1 in 7,573, and Trisomy 13 (Patau syndrome) 1 in 22,719 86.  Maternal age 
plays a significant role in chromosomal abnormalities. At age 35 the rate of chromosomal 
abnormalities in live births is 0.52% but increases to 5.57% by age 45 86. Despite the high 
rate of abnormalities, it is estimated that 30% of all chromosomal abnormalities will not 
be detected 88 hence the need for screening techniques.  
Prenatal screening protocols such as chorionic villus sampling and amniotic fluid 
sampling are the current gold standard 89 but these invasive methods have a miscarriage 
rate of 1 out of 100 33. Noninvasive prenatal testing (NIPT) using cell free fetal DNA 
(cffDNA) in maternal plasma has many advantages over invasive techniques. NIPT no 
longer has a risk of fetal loss and greatly reduces pain and complications 34. In a meta-
analysis of 37 studies, NIPT outperforms traditional invasive methods for Trisomy 21 
with a sensitivity of 99.2% and specificity of 99.91% while performance for other 
trisomies (13, 18, sex) was slightly lower 90. Initial studies were largely conducted using 
 33 
pools of high-risk pregnancies which have a higher probability of chromosomal 
abnormalities than the general population 47. One study examined NIPT performance in 
the general population and found NIPT protocols had lower positive predictive power but 
still outperformed traditional invasive protocols 91. Despite the many advantages of 
NIPT, there are several obstacles before NIPT supplants traditional invasive procedures 
including: cost, protocol accessibility, and cytogenetic diagnostic performance on other 
abnormalities 47. 
4.2 Cancer Detection 
Aneuploidy is present in most types of cancers 92 and malignancy is directly 
proportional to amount of abnormalities 32. Unlike single chromosomal abnormalities 
observed in fetal screening, cancers typically have multiple chromosomal abnormalities 
93. Not all chromosomal arms are likely to be altered and gains/losses do not occur in the 
same frequency. The most frequently observed gains are: 1q, 5p, 7p, 8q, 20q while the 
most common losses are 4q, 6q, 8p, 13q, 17p 93. There is a pressing need to detect 
chromosomal abnormalities in cancer.  
Invasive biopsies are the gold standard for retrieving cancer tissue for cancer 
diagnosis. Biopsies, however, can cause severe pain 34 and occur in tissue types that are 
difficult to sample.  Like NIPT, genetic screening using cell free DNA has many 
advantages over invasive techniques. Tumor DNA (cftDNA) can be retrieved from blood, 
urine, and stool and comprises 0.01% to 90% of all circulating DNA 35; 94. Malignancies 
with as few as 50 million cells can be detected which is far below the resolution of 
radiological imagining and suggests that cftDNA could be used early cancer screening 94.  
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4.3 Current Techniques to Detect Aneuploidy 
4.3.1 G-Banding 
G-Banding was the first method developed to detect chromosomal abnormalities 
95. In this procedure, cells in mitosis are treated with colchicine causing the microtubules 
to disrupt and arrest in metaphase. Cells are then fixed and treated on a glass microscope 
slide with Giemsa dye. The dye produces distinct and reproducible patterns on each 
chromosome for study. 
4.3.2 Fluorescence In Situ Hybridization (FISH)   
Fluorescence In Situ Hybridization (FISH) attaches a fluorescently labeled DNA 
probe that can bind to chromosomal regions with sequences are highly complementary. 
Researchers use fluorescence microscopy to identify chromosomal locations where the 
bound probe resides 96. This protocol can be expanded to include different color probes 
for use on all chromosomes and is often referred to as multiplex-FISH 97; 98. 
4.3.3 Comparative Genome Hybridization (CGH) 
 Comparative Genome Hybridization isolates and fragments DNA for both a test 
and control sample. One sample is labeled with red fluorescent dye and the other sample 
is labeled with green dye. The dyed fragments compete and bind to different probes. 
Researchers can assess whether a region is amplified, deleted, or unaltered based on the 
whether the corresponding chromosomal region appears more green or red. The time 
intensive standard CGH protocol was extended to include thousands or base-pair 
fragment on a microchip and the resulting color analysis has been automated 
(microarray). The information from a single microarray experiment is more than 
thousands of FISH experiments 99. 
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4.3.4 Digital Karyotype  
 Digital Karyotype quantifies short sequences of DNA from specified loci over the 
genome. Aneuploidies can be identified based on the read depth at a loci of interest. 
Methods have been designed to identify both small and very large aneuploidies, with a 
wide range of techniques including circular binary segmentation, hidden Markov models, 
expectation maximization and mean-shift (as reviewed in 46).  
The initial focus of read depth methods was whole genome sequencing, in which 
reads are expected to be randomly distributed across the genome.  Under the assumption 
that reads are uniformly and independently distributed, regions of normal copy number 
are expected to follow a Poisson or Normal distribution 46; 100.  These approaches require 
correction for biases induced by differing GC content across the genome and uneven 
representation of genomic regions in library preparation 46.  Read depth methods have 
subsequently been extended to targeted, capture-based sequencing protocols, requiring 
modification of segmentation algorithms and introduction of alternate techniques, such as 
regression models and PCA.  Targeted sequencing introduces coverage discontinuities, 
and increased variability due to differences in capture efficiency 46. Several recent 
methods also leverage randomly distributed off-target reads to improve accuracy 101; 102.    
Amplicon-based sequencing approaches also have utility for aneuploidy 
detection, but fewer aneuploidy analytical methods have been developed for this purpose.  
Amplicon-based protocols can achieve high coverage depth at relatively low cost, and 
they are an attractive alternative to WGS and targeted protocols for small amounts of 
DNA at low neoplastic fractions 103; 104. Reads from amplicon sequencing are limited to a 
relatively small number of discrete loci.  In addition to being discontinuous, they are not 
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randomly distributed, which makes it difficult to apply existing mathematical models of 
read depth coverage.  Several studies have reverted to Z-score approaches in which read 
depth at a locus is compared to an overall mean, and aneuploidy is called when the 
centered read depth exceeds 3-5 standard deviations away from the mean 105-107.  In a 
refinement of this approach, read depth may be converted to a ratio between test sample 
and a control at the locus, using either a matched normal or a pool of selected control 
samples 108.  In the next chapter, I present a new analytical approach for aneuploidy 
detection from FastSeqs amplicon sequencing of long interspersed nucleotide elements 
(LINEs).  FastSeqs is fast and efficient but yields a read depth distribution that is not well 
handled by computational methods developed for WGS and targeted sequencing.  I use a 
within-sample approach to identify chromosome arm level gains and losses and a 
machine learning method to summarize the general aneuploidy of a sample.     
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Chapter 5:   WALDO: Within-sample 
AneupLoidy DiscOvery  
Here, I introduce a novel computational framework entitled WALDO (Within-
sample AneupLoidy DiscOvery) (Figure 2). This method contributes several 
methodological advances to amplicon-based aneuploidy detection.  The method identifies 
groups of genomic intervals distributed throughout all chromosomes, whose read depths 
track together in DNA from normal individuals, because they have similar amplification 
properties. Although the reads are not randomly distributed across the genome, within 
these groups, they are approximately random and Normally distributed.  For a test sample 
of interest, the method uses a within-sample approach to parameterize a Normal 
distribution (mean and variance) of read depths for each group.   It is expected that the 
total read depth, summed over all genomic intervals in a euploid chromosome arm, will 
not deviate significantly from its theoretical expectation.  A convenient property of the 
Normal distribution is that the theoretical mean and variance can be computed by 
summing the group means and the group variances of the chromosome arm intervals. To 
my knowledge, this is the first time that within-sample methods have been applied to 
amplicon sequencing.   
 I show that this framework can be applied to identify chromosome arm gains or 
losses, including allele-specific gains and losses.  Furthermore, this method incorporates 
machine learning to make generalized aneuploidy calls, in which samples are classified 
according to their aneuploidy status. This study presents a significant advance over 
previous work.  This protocol reduces the false positive rate with respect to calling 
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aneuploid chromosome arms, and I show that the method can be applied robustly on 
thousands of diverse samples, including primary biopsy samples of 11 different tumor 
types with high neoplastic fraction and samples with fractions as low as 1%.  While very 
low neoplastic fractions have been previously reported, these studies have been limited to 
small sample size (<50 samples) 106; 109; 110 without the need to handle batch effect issues.   
Matched normal samples are not required for the aneuploidy calling method, but if 
matched normals are available for a test sample, this method can also call somatic single 
base substitution and indel mutations, estimate mutation load and identify carcinogen 




Figure 2: WALDO Overview 
WALDO identifies chromosome arm gains or losses, including allele-specific gains and 
losses without the use of a normal. When matched normals are available for a test 
sample, this method can also call somatic single base substitution and indel mutations, 
estimate mutation load and identify carcinogen signatures and microsatellite instability 
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5.1 Sample Collection 
Sample collection 
 
562 primary tumors (16 of which had adjacent normal tissue), and 176 normal 
white blood cells (WBC) were collected. The primary tumors consisted of (45 bladder 
cancers, 56 breast cancers, 302 colon and colorectal cancers, 26 esophageal cancers, 37 
head and neck, 27 liver cancers, 9 ovarian cancers, 22 uterine cancers, 22 gastric cancers, 
10 urothelial carcinomas of the upper urinary tract, 6 colorectal cancers with 
microsatellite instability and 32 colorectal adenomas.  Peripheral white-blood-cell (WBC) 
and plasma samples were collected from healthy individuals. All individuals provided 
written informed consent after approval by the institutional review board of The Johns 
Hopkins University.   
5.2 Fast-SeqS and Safe-SeqS 
 
For each sample, FAST-SeqS was used to amplify approximately 38,000 
amplicons, with a single primer pair 105, and massively parallel sequencing was 
performed on Illumina instruments (HiSeq, MiSeq). During amplification, degenerate 
bases at the 5’ end of the primer were used as barcodes to uniquely label each DNA 
template molecule (Safe-SeqS 111.  To reduce the possibility that a DNA template 
molecule would be counted multiple times, the barcodes were used to quantify unique 
templates (UIDs).  The UIDs were used instead of raw reads.  Samples were sequenced to 
a depth of 15-25 million reads using 3-15 million UIDs.  Normal replicates were included 
in every sequencing run as a positive control, and replicates were used to capture 
differences resulting from stochastic and experimental variability.  
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5.3 Sample alignment and genomic interval grouping 
For each sample, read length was 150bp and targeted read depth was 25M.  Reads 
were grouped into families sharing a common SAFE-seqs barcode, yielding 3-15M 
unique reads (UIDs).  Bowtie2 was used to align reads to human reference genome 
assembly GRC37. Next, 24,720 single nucleotide and 1,500 insertion and deletion 
polymorphisms with MAF>1% were extracted from 1000G 112 (Phase 3 20130502).  I 
identified 37,669  exact matches (33,844 on autosomes) to the reference genome, 
allowing also for exact matches that included a common polymorphism.   For efficiency. 
the genomic positions and amplicon sequences were stored and used to directly map 
amplicons from subsequent samples, without a sequence alignment step. 
Even when there was no aneuploidy present, it is expected that the number of 
UIDs that mapped to a genomic region would be variable, based on stochastic and 
experimental factors.  This variability was controlled for by grouping genomic intervals 
with similar UID depth across all chromosomes in multiple normal samples.  Intervals 
consisted of 500Kb of genomic DNA, which spanned one or more LINEs, with a total 
4361 regions across 39 non-acrocentric chromosomes.   The 500Kb length produced 
good performance by the clustering algorithm.  Increasing the length reduced its power to 
identify similar intervals and decreasing the length increased computational expense. 
  Genomic interval grouping was performed for each test sample by selecting a set of 
normal (non-aneuploid) samples which had similar distributions of DNA amplicon sizes 
to that sample.   Briefly, during PCR, smaller amplicons are preferentially amplified 105; 
113. The distribution of amplicon sizes depends on both the batch in which a sample is 
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amplified and its source.   For each test sample p, I selected the seven normal samples 







where, p_n and q_n are the fraction of amplicons of size n in samples p and q, and the 
sum is over all amplicon sizes in the two samples.  The variance of amplicon sequence 
depth across samples was estimated with maximum likelihood and the top 1% were 
removed.  Additionally, any amplicons with < 10 UIDs in one sample and > 50 UIDs in 
any other sample were removed.  Large differences among normal samples were most 
likely caused by private sequence variants that were not mapped to the correct amplicon.  
LINE-spanning genomic intervals were clustered by their UID depth distributions, after 
scaling, across the selected normal samples.  Scaled UID counts were computed by 
subtracting the mean and dividing by the standard deviation of UID counts in each 
sample.  
First, each chromosome interval i was assigned to a primary cluster Ci .  Next, 
UID depth distribution of i  across all samples was compared to all other intervals i’ that 
occurred on the remaining 21 autosomal chromosomes, across all samples.  Since I was 
looking for similarity, I tested for insignificant results (paired t-test p>0.05, f-test 
p>0.05).   If an i’ was similar to i , it was added to cluster Ci .  This procedure allowed for 
an interval i to be the sole member of its primary cluster and/or belong to more than one 
cluster.  The average cluster contained ~200 intervals (Figure 3).  The basic protocol 
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uses normal samples only for genomic interval grouping, and all statistical tests are done 




Figure 3: Representative Sample to illustrate the Number of Genomic Intervals 
included in a Cluster 
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5.4 Calling chromosome arm aneuploidies in a test sample 
 
While FastSeqs UIDs were not randomly distributed, UIDs in each genomic 
interval group yielded by the protocol follow an approximately normal distribution 
(Figure 4).   For a test sample, maximum likelihood estimation determines the UID depth 
mean 𝜇  and variance 𝜎2  of each the 4,361 genomic interval groups.  This improved the 
robustness of these estimates by iteratively removing outliers from the groups.  For each 
group, I flagged any outlier interval with (min(2* CDF(𝜇, 𝜎𝑖
2), 2*(1-CDF)) 1-CDF(𝜇, 𝜎𝑖
2) 
<  (=0.01 in this work), and the flagged interval was removed from all groups.  Next, 
the and parameters of each group were re-estimated by maximum likelihood.  The two 








To infer whether a chromosome arm was aneuploid, I estimated the statistical 
significance of the total UID count of the arm, by comparing to the 𝜇  and 𝜎2  
parameters of the primary cluster of each interval on the arm.  Because sums of normally 
distributed random variables were also normally distributed random variables, the 
calculation was straightforward (Equation 3).  Using 
Equation 3 











a chromosome arm was aneuploid if the following two-sided test was significant, 








1 )) < .  To distinguish between 
chromosome arm gains and losses, I performed the one-sided test.  For gains, 1-




1  <  and for losses, CDF(∑ 𝜇𝑖, ∑ 𝜎𝑖
2𝐼
1 )  <  
𝐼
1  .  For each chromosome 




1 .   Positive 
Z-scores represented gains and negative Z-scores represented losses.  
5.5 Arm level Allelic Imbalance 
 
Common polymorphisms from 1000G (24,720 single nucleotide and 1,500 indels, 
MAF>1%) were used as candidate heterozygous sites in the samples.  For each of the 677 
normal samples, I identified polymorphic sites that could be confidently called as 
heterozygous and diploid, based on their B-allele frequencies (BAF) (0.4<BAF<0.6), 
where BAF = #non-reference reads / total reads.  BAFs were modeled at these sites as 
random variables from a normal distribution with mean 0.5 and a variance that depended 
on UID depth. The variance was estimated with maximum likelihood, as a function of 
UID depth (Figure 5).   Further analysis was restricted to these sites.   
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To infer whether a chromosome arm in a test sample harbored allelic imbalance, I 
identified the subset of polymorphic sites at which both alleles were present in that 
sample and with sufficient UID depth (>25 UIDs). At each site, I compared the observed 
BAF with the normal distribution, using the expected variance for the observed UID 
depth, yielding a two-sided P-value.  All p-values on a chromosome arm were Z-
transformed and combined with a weighted Stouffer’s method (Equation 4), with the 










𝑤𝑖 = 𝑈𝐼𝐷 𝐷𝑒𝑝𝑡ℎ 𝑎𝑡 𝑉𝑎𝑟𝑖𝑎𝑛𝑡 𝑖 
𝑍𝑖 = 𝑍 𝑠𝑐𝑜𝑟𝑒 𝑎𝑡 𝑉𝑎𝑟𝑖𝑎𝑛𝑡 𝑖 
𝑘 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓  𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑠 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑜𝑛 𝑎 𝑐ℎ𝑟𝑜𝑚𝑠𝑜𝑚𝑒 𝑎𝑟𝑚 
A chromosome arm had allelic imbalance if the resulting Z score was greater than a 




Figure 5: Empirically Estimated B allele Frequency Variance vs UID Depth. 
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5.6 Generalized Aneuploidy Detection 
 
 For samples with lower fractions of neoplastic cells, it may not be possible to call 
specific aneuploid chromosome arms with high confidence.  An alternative approach was 
to consider all chromosome arms collectively.    
 A two-class support vector machine (SVM 114 ) was trained to discriminate 
between a negative class of normal samples with no aneuploidy and a positive class of 
synthetic samples in which aneuploidy was spiked-in.   The training set contained 677 
WBC normal samples (3M-15M UIDs) and 3,150 synthetic samples.  SVM training was 
done with the e1071 package in R, using radial basis kernel and default parameters 115.   
Each sample had 34 Z-score features, representing chromosome arm gains and losses. 
The following arms were not included, because they were consistently miscalled as 
aneuploid in normal samples: 4q, 17q, 19p, 19q, 22q. 
 Synthetic aneuploid samples were generated by spiking in aneuploid chromosome 
arms to 63 of the normal WBC samples, which contained at least 9M UIDs. They were 
designed to represent low neoplastic cell fractions (0.005, 0.01) and degrees of 
aneuploidy (5,10,15,20, or 25 chromosome arm gains or losses).  Each synthetic sample 
contained exactly 9M UIDs.  Spike-ins were implemented by duplicating or subtracting 
UIDs from selected chromosome arms.  I made a number of simplifying assumptions 
when generating synthetics: 1) all chromosome arms were independent; 2) chromosome 
arm alterations in a sample occurred in the same fraction of neoplastic cells; 3) alterations 
were restricted to a single copy gain or loss per arm; 4) duplication or subtraction of 
UIDs was restricted to UIDs that matched the reference genome.   
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The spike-ins were intended to represent a realistic range of arm gains and losses, 
based on the total numbers observed in the primary tumor samples.  To ensure a wide 









To balance the number of positive and negative examples used to train the SVM, 
the positive class was randomly subsampled to match the size of the negative class.   Ten 
two-class SVMs were trained, by subsampling the positive class ten times, then training 
an SVM on the subsampled positive class and the negative class.  Each sample to be 
classified was scored by all ten SVMs, and the ten scores were averaged to yield a final 
score.   
 Samples may have a wide range of UID depths, which I observed to confound 
SVM scoring, so that samples with very low UID depth received artificially high scores. I 
controlled for UID depth by modeling the change in SVM scores as a function of UID 
depth in normal samples.  Each of the 63 WBC normal samples was randomly down-
sampled to yield ten replicate synthetic samples of UID depth ranging from 100K to 9M.   
Gain/loss Z-scores were computed for all chromosome arms and each synthetic sample 
was scored by ten SVMs and the scores were averaged, using the protocol previously 
described.   This procedure yielded 630 SVM scores for synthetic normal samples at each 
UID depth.  All scores were converted to ratios by finding the sample at each UID depth 
with the minimum SVM score and dividing all scores at the same depth by that value.  
The average ratio r at each depth decreased monotonically as a function of increasing 
UID depth Figure 7).  The relation between UID depth and SVM score was model using 
Equation 5 (A=-7.076*10^-7 and B=-1.946*10^-1) and raw SVM scores were corrected 









Figure 7: Raw SVM Scores as function of UID Depth 
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Finally, because the SVM was designed for difficult-to-detect aneuploidies, 
before classifying a sample, I checked whether it contained at least one aneuploid 
chromosome arm that could be identified with high confidence.  If such a chromosome 
arm was present, the sample was called as aneuploid and SVM classification was not 
applied.  A “high confidence” call was made if a chromosome received a Z-score (gain, 
loss, or allelic imbalance) that was an extreme outlier (±4 𝜎 from max or min Z-score) 
with respect to the distribution of Z-scores seen in the 677 normal WBC samples.  
5.7 Somatic sequence mutations and microsatellite instability 
(MSI) 
When matched normal samples were available, somatic single nucleotide 
substitution (SBS), insertion and deletion (indel) mutations based on FastSeqs LINE 
amplicon sequences and alignments could be identified.  The SBS mutations were 
identified by directly comparing amplicons from the test sample with amplicons from the 
matched normal, and did not require any alignment to the reference genome.   I used the 
following conservative thresholds.  Amplicons with fewer than 200 reads and 50 UIDs in 
the matched normal were excluded.  Amplicons that occurred only in the test sample 
were identified, and any of these amplicons with fewer than 20 reads and 5 UIDs were 
excluded.  The remaining reads were compared position-wise to the reads from the 
normal sample to identify test sample reads that differed from any normal read by exactly 
one nucleotide substitution.   This procedure enabled us to call SBS somatic mutations 
and subsequently estimate mutation load and the presence of known carcinogen 
signatures.   
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 Somatic indel mutations were called by aligning amplicons from the test sample 
and matched normal sample to the reference genome (GRc37) with Bowtie2 116.  To 
reduce potentially including PCR artifacts, amplicons with a ratio of reads to UIDs less 
than two were excluded.  If Bowtie2 reported an insertion or deletion in the test sample 
but not in the matched normal, and the amplicon had >= 10 UIDs in the test sample and 
in the matched normal, it was considered to harbor a somatic indel then detect the number 
of somatic indels in monotracts of > 3 nucleotides.  There were 17,488 of these 
monotracts in the FastSeqs amplicons. The number of somatic monotract indels in a 
normal sample can be modeled using a Poisson distribution where lambda is the average 
number of somatic indels resulting of a sequencing artifact. Samples with statistically 
significant quatities of somatic indels in monotracts can be identified as MSI. 
5.8 Sample Identification 
 This protocol can be used to estimate concordance between polymorphic sites in 
two samples of interest.  Samples were sequenced and all amplicons were aligned to 
reference genome GRC37 with Bowtie2.  Amplicons with <10 UIDs in either sample 
were excluded.  The 1000G common polymorphisms (Sample alignment and genomic 
interval grouping) were used to identify the genotypes at 26,220 sites in each sample.  
Each polymorphic site was called as “0”  (homozygous reference,  >0.95 UIDs matching 
reference allele), “1” (heterozygous, 0.05-0.95 UIDS matching either reference or 
alternate allele,  >10 UIDs for each allele),  or “2” (homozyous alternate, >0.95 UIDs 
matching alternate allele). A broad UID range was used to call heterozygous sites to 
ensure that heterozygosity could be detected in tumor samples  harboring allelic 
imbalance.  To compare two samples, I considered polymorphic sites with sufficient 
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amplicon coverage in both samples and counted the number of sites that agreed on “0”, 
“1”, and “2”.  Concordance was the number of matched polymorphic sites divided by the 




Chapter 6: WALDO Performance and 
Applications 
First, I compared this protocol to whole genome sequencing and then performance 
was assessed on the ability to detect: 1) single chromosome arm events using synthetic 
data; 2) identifying chromosome arm aneuploidies in primary tumors; 3) detecting 
general aneuploidy using synthetic data; and 4) Mutation load, carcinogenic signatures, 
and MSI. 
6.1 Comparison to Whole Genome Sequencing 
 
Amplifying and sequencing a discrete set of locations using a single primer has numerous 
experimental and computational advantages over whole genome sequencing. Here, I 
directly compare the performance of WALDO to whole genome sequencing. To my 
knowledge, WISECONDOR is the only free publically available prenatal screening 
protocol for whole genome sequencing 117. WISECONDOR partitions the genome into 
intervals. The genomic intervals are grouped together based on similar properties. These 
groups of intervals are used to perform statistical testing. Chromosomal aneuploidies can 
be detected using a sliding window approach that identifies intervals along a chromosome 
that have been altered. According to the authors of WISECONDOR, cases and controls 
should always come be performed on the same sequencing machine, aligned using BWA 
118, sorted using the picard software (http://broadinstitute.github.io/picard), and filtered 
using samtools 119. Default parameters of WISECONDOR were used and Trisomy 21 
was called using the “windowed, bin test.” 
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In order to directly compare these approaches, 12 mixtures were created using 2 
ng of normal DNA and 0.2 ng of trisomy 21 DNA. The mixtures were created to replicate 
typical fetal fractions in noninvasive prenatal testing (approximately 10%). Trisomy 21 
and normal samples were sequenced and analyzed using both FAST-SeqS + WALDO 
and whole genome sequencing + WISECONDOR. Sensitivity (ability to correctly 
identify Trisomy 21) and specificity (ability to correctly identify normal samples as 
normal) were calculated at different read depths. WALDO identifies chromosome gains 
and losses at different thresholds depending on the desired alpha where as 
WISECONDOR calls chromosome gains and losses depending on the number of altered 
genomic intervals. WISECONDOR does not provide a way to estimate the type I error 
rate and the authors report no false positives for chromosome 21.  While both methods 
can reliably detect trisomy 21 at high specificities required for NIPT, WALDO and 







Figure 8: Comparison to Whole Genome Sequencing 
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6.2 Detection of Single Chromosome Arm Events Using 
Synthetic Data 
I generated synthetic aneuploid samples derived from 63 normal WBC samples. 
677 normal WBC samples and the synthetic samples were used to evaluate performance 
on single chromosome arm events (gains/losses and allelic imbalance). For each of the 63 
samples, gains and losses were generated for each chromosome arm at various cell 
fractions. WALDO provides a statistical framework to assess the significance of each 
chromosome arm. Chromosome arm gains/losses and allelic imbalance can be identified 
at the desired alpha (type I error rate). I assessed performance for all chromosome arms 
(Figure 9). Sensitivity is the ability to correctly identify a chromosome arm (gain/loss or 
allelic imbalance) at a given statistical alpha. Specificity is the ability to correctly identify 
normal chromosome arms as normal for a given alpha. In theory, specificity is equal to 1 
minus alpha (1- the type I error rate). For gains/losses across all chromosomes the 
specificities for alphas 0.05, 0.01, and 0.005 were 0.969, 0.995, and 0.998 respectively. 
The observed statistical significances were slightly more conservative than expected for a 
given alpha. For allelic imbalance across all chromosomes the specificities for alphas 
0.05, 0.01, and 0.005 were 0.946, 0.970, and 0.992 respectively. The observed statistical 
significances were slightly less conservative than expected. Gain/losses sensitivity 
approaches 100% for cell fractions above 5%. Sensitivity can be improved depending on 
the application and acceptable type I error rate. Allelic imbalance, however, was a much 
weaker signal and not informative for cell fractions below 5%. Performance varied 
depending on the specific chromosome arm and unsurprisingly larger chromosomes were 
much easier to detect gains/losses. NIPT testing typically evaluates trisomies 13, 18, and 
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21. Fetal cell fractions typically observed in NIPT are approximately 10% and testing is 
often not performed on cell fractions < 5% 117. At 10 % cell fraction using an alpha of 
0.005, WALDO had sensitivities 100%,100%, 100% and specificities 99.7%, 100%, 
99.4% for 13q,18q,21q respectively. For clinical use, thresholds should be optimized for 





Figure 9: Chromosome Arm Aneuploidy Detection at alpha = 0.05 
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6.2 Identifying Chromosome Arm Aneuploidies in Tumors  
 I applied the framework to identify single chromosome arm gains and losses in 
tumor samples. I analyzed aneuploidy in 546 primary tumors that consisted of 45 bladder 
urothelial carcinomas (BRCA), 56 breast invasive carcinomas (BRCA), 302 colon and 
colorectal adenocarcinomas (COAD and COADREAD) cancers, 26 esophageal 
carcinomas (ESCA), 37 head and neck squamous cell carcinomas (HNSC), 27 liver 
cancers (LIHC), 9 ovarian cancers (OV), 22 uterine corpus endometrial carcinomas 
(UCEC), 22 stomach adenocarcinomas (STAD), and 32 colorectal adenomas.  I identified 
gains and losses using a z threshold of 3 and -3 and quantified the total numbers of 
aneuploidies in each sample. I compared the WALDO aneuploidies to the aneuploidies 
detected from array CGH in The Cancer Genome Atlas (TCGA) 120 (Table 5). While I do 
not expect the analyses to match exactly because different samples were being used, the 
patters in specific cancer types as well as across cancer types should be very similar. On 
average WALDO identified more aneuploidies than the TCGA analysis (15.6 vs 13.0) but 
the distribution of altered chromosome arms was very similar (Figure 10) suggesting that 
WALDO can chromosomal events in actual cancer tumors. 
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ALL 15.6 13.0 7.9 6.2 7.7 6.7 
BRCA 16.5 13.0 8.2 6.0 8.3 7.0 
BLCA 16.4 13.5 9.0 6.9 7.4 6.7 
COAD 
COADREAD 15.0 12.3 7.1 6.7 7.9 5.6 
ESCA 18.7 16.0 9.7 7.8 8.9 8.2 
HNSC 15.6 11.1 8.5 5.9 7.1 5.2 
LIHC 15.6 11.6 8.1 5.4 7.5 6.2 
OV 20.4 19.3 10.0 7.4 10.4 11.8 
UCEC 5.9 7.3 3.4 3.6 2.5 3.7 
STAD 16.9 10.7 9.1 5.6 7.8 5.0 
Colorectal 





Figure 10: Distribution of Aneuploid Chromosomes Arms across All Cancer Types 
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6.3 Detection of General Aneuploidy Using Synthetic Data 
 
Aneuploidy is a general feature of neoplastic cells 121.  I investigated whether 
generalized aneuploidy prediction (identifying the presence of any aneuploid 
chromosomes) could discriminate between synthetic aneuploid samples and normal 
samples. Synthetic samples were created with multiple aneuploidies (5,10,15,20,25) at 
various cell fractions. WALDO summarizes the chromosome arm Z scores using a 
supervised machine learning method. To evaluate the discriminatory power of WALDO 
generalized aneuploidy score, I partitioned the training set into 11 equal folds (11 folds of 
16 WBC samples). Technical and synthetic replicates were restricted to the same fold. 
WALDO detect aneuploidy in reliable detect aneuploidy at close to 100% of the time in 
samples with more than 1% neoplastic content at very high levels of specificity (99%). 
Samples with low neoplastic content (0.5%, 1%) can also be detected at high levels of 
specificity (99%) when there is a large number of gains and losses present in the sample 
(Figure 11). Performance was measure at 9M UIDs, however, increasing the number of 





Figure 11: Cross Validation Performance of Generalized Aneuploidy Detection on 




Figure 12: Generalized Aneuploidy Performance on High UID Depth Samples 
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6.4 Mutation load, carcinogenic signatures, MSI 
 
 To my knowledge, amplicon sequencing has not previously been used to estimate 
somatic mutation load, or to identify carcinogenic signatures or microsatellite instability 
(MSI) in primary tumor samples.  Whole-exome or whole-genome sequencing protocols 
are typically chosen.  This obtained good estimates of mutation load in 10 urothelial 
carcinomas of the upper urinary tract (UTUCs), to identify an aristolochic acid mutation 
signature in 6 of these UTUCs, and to identify MSI in 6 mismatch-repair (MMR) 
deficient colorectal cancers (CRCs).  This required matched normal samples to call 
somatic single nucleotide substitution (SBS) mutations and indels.  I applied Fast-SeqS 
and Safe-SeqS amplicon sequencing and the somatic mutation calling protocol.  For each 
sample, the total number of somatic SBS mutations was counted (mutation load) (Figure 
13) and the fraction of each possible nucleotide substitution was determined (A->T, A-
>C, etc.) (mutation spectrum) .  Sample mutation load and mutation spectrum were 
highly correlated with estimates based on previous whole exome sequencing 122. 
(R2=0.98 and 0.95, respectively).  The mutation spectrum noticeably contained the 



































Somatic Mutations in Exome Sequencing
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Fraction of A:T>T:A Somatic SBS Mutations in Exome Sequencing  
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Furthermore, the FastSeqs amplicons harbored 17,488 monotracts of >3 
nucleotides, which enabled identification of MSI, by counting the number of somatic 
indels that occurred in the monotracts and identifying statistically significant samples 
(See 5.7 Somatic sequence mutations and microsatellite instability (MSI)).  I applied this 
approach to the 6 MSI colorectal tumors and 10 UTUC tumors (Table 6). As a negative 
control, the 16 matched normal samples were partitioned into equal parts and somatic 
indels were called. No normal samples were statistically significant. All MSI tumors were 
statistically significant. SB 102 PT was the one statistically significant UTUC tumor. SB 
102 PT  had 3,112 somatic mutations identified in exome sequencing 122. The other 
UTUC tumors had ~100 somatic mutations identified during exome sequencing so it was 














Co 083  MSI 27 1.25E-30 
Co 083 N Normal 0 0.632 
Co 086 MSI 29 1.43E-33 
Co 086 N Normal 1 0.264 
Co 088 MSI 30 4.62E-35 
Co 088 N  Normal 0 0.632 
Cx 002 MSI 10 1.00E-08 
Cx 002 N Normal 0 0.632 
Cx 010 MSI 45 6.83E-59 
Cx 010 N Normal 0 0.632 
Hx 075  MSI 67 1.51E-97 
Hx 075 N  Normal 0 0.632 
SB 101 N Normal 0 0.632 
SB 101 PT UTUC 1 0.264 
SB 102 N Normal 0 0.632 
SB 102 PT UTUC 20 7.54E-21 
SB 103 N Normal 0 0.632 
SB 103 PT UTUC 2 0.0803 
SB 104 N Normal 1 0.264 
SB 104 PT UTUC 0 0.632 
SB 105 N  Normal 0 0.632 
SB 105 PT UTUTC 1 0.264 
SB 106 N Normal 0 0.632 
SB 106 PT  UTUC 0 0.632 
SB 111 N Normal 1 0.264 
SB 111 PT UTUC 0 0.632 
SB 112 N Normal 0 0.632 
SB 112 PT UTUC 0 0.632 
SB 113 N Normal 0 0.632 
SB 113 PT  UTUC 0 0.632 
SB 114 N Normal 0 0.632 
SB 114 PT  UTUC 0 0.632 
SB 115 N Normal 0 0.632 
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SB 115 PT  UTUC 1 0.264 
SB 116 N Normal 0 0.632 




6.5 Applications and Discussion 
 
 Aneuploidy is a feature of most cancer cells, and cancer malignancy is related to 
the amount of aneuploidy.  In the past decade, many techniques have been developed to 
detect aneuploidy based on whole genome and targeted sequencing protocols.  Here, I 
introduce a new analytical approach for aneuploidy detection from FastSeqs amplicon 
sequencing of long interspersed nucleotide elements (LINEs).  FastSeqs is fast and 
efficient but yields a read depth distribution that is not well handled by computational 
methods developed for WGS and targeted sequencing.  This method uses a within-sample 
approach to identify chromosome arm level gains and losses and a machine learning 
method to summarize the general aneuploidy of a sample.  In collaboration with the 
Johns Hopkins Ludwig Cancer Center, this method is currently being applied to 
numerous ongoing studies. This method is being used to detect aneuploidy in pancreatic 








Chapter 7: Concluding Remarks and Future 
Work 
 Advances in sequencing technology have greatly reduced the costs incurred in 
collecting raw sequencing data. Academic laboratories and researchers therefore now 
have access to very large datasets of genomic alterations but limited time and 
computational resources to analyze their potential biological importance. Computational 
tools can assess the potential impact genetic variation has upon human health. These tools 
can narrow down long lists of variants to identify a small subset of candidate variants. 
Despite the utility of computational tools, most can only predict the impact of single 
nucleotide changes. My dissertation introduced two novel methods that can be applied to 
genetic variation beyond single nucleotide changes.  
7.1 VEST-indel 
 
In the first part of my thesis, I develop a method for predicting indel 
pathogenicity. VEST-indel differs from current indel classifiers that were developed to 
predict the impact of indels on protein structure or function. VEST-indel has substantial 
improvement in specificity relative to existing methods, highlighting reductions in falsely 
classifying neutral variants as pathogenic largely from the incorporation of a new text 
mining feature that captures the known relevance of a gene to human health. VEST-indel 
predicts pathogenicity in both inframe and frameshift indel and can be used in 
combination with the original VEST missense method to perform joint prioritization. 
This enables researchers to perform single pass sorting on all the sequence variants 
detected in their sequencing studies.  
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I demonstrated the utility of combining in-frame, frameshift, and missense 
variants for reliable joint prioritization. In the future, I would like to see the Variant 
Effect Scoring Tool extended beyond these three variant types. I think there is a pressing 
need to create pathogenicity predictors specifically designed for splice variants, 
regulatory variants, as well as variants that disrupt or introduce stop codons. Each of 
these predictors could be combined using the same statistical framework proposed in my 
thesis. Currently, the CADD method already provides joint prioritization across all of 
these variant types. The CADD method, however, was designed very generally and not 
for any particular variant type. In my thesis, I demonstrated, the method has significant 
limitations. I believe that developing individual predictors for each variant type and then 
combining the scores using a statistical framework can greatly improve single pass 




Aneuploidy or abnormal numbers of chromosomes, is an important feature in both 
prenatal screening and cancer detection. I introduce a new analytical approach for 
aneuploidy detection from FastSeqs amplicon sequencing of long interspersed nucleotide 
elements (LINEs).  FastSeqs is fast and efficient but yields a read depth distribution that 
is not well handled by computational methods developed for WGS and targeted 
sequencing.  This method uses a within-sample approach to identify chromosome arm 
level gains and losses and a machine learning method to summarize the general 
aneuploidy of a sample. It can also be used to identify mutation load, carcinogen 
signatures, and microsatellite instability. It is effective on samples containing only a few 
ng of DNA and as little as 1% neoplastic content. 
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I believe aneuploidy detection can be improved with the presence of a matched 
normal sample. With a matched normal, I believe WALDO could detect aneuploidy in 
much less than 1% neoplastic content. FastSeqS amplicons are highly repetitive. Private 
non-reference alleles can cause mis-mapped amplicons during alignment. These mis-
mapped amplicons appear as amplifications or deletions in a test sample. WALDO was 
designed to achieve a high specificity and treated potential mis-mapping as noise. With a 
matched normals, private variants could be detected thus improving alignment and 
ultimately reducing noise when identifying aneuploidy. 
7.3 Conclusion 
   
High-throughput sequencing technology routinely generates millions of genetic 
variants. Computational algorithms can reduce the time required to analyze the potential 
impact on disease etiology of the many genetic variants detected and there is a pressing 
need for tools that can handle variation beyond single nucleotide changes. In this 
dissertation, I introduced two novel computational methods (VEST-indel and WALDO) 
for pathogenicity prediction of indels, aneuploidy detection, and microsatellite detection 











Figure S 1: Histograms for allele length and minor allele frequency for selected data 
sets. Indel length probability density for both frameshift (A) and in-frame (B) indels, 
separated by training and testing datasets. Figure C plots the minor allele frequency 
(MAF) probability density for ESP6500 indels used in the benign training set. 
Pathogenic variants from HGMD and ClinVar, and benign interspecies indels, do not 
have reported MAFs and are therefore absent from Figure S1.  
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Table S 1: All Features Considered During VEST-indel Development: 
 
Feature 










conservation Exon Conservation ExonConservation 10.76 4 10.8 3 
  
      
  
Hidden Markov 
model score of 
alanine substitution 
at first position 
where indel occurs 
from 46-way 
mammalian 
genome alignments AluSubPHC 10.67 5 11.56 2 
DNA natural 
variation ExonSnpDensity ExonSnpDensity 6.68 8 7.48 5 
Gene-level 
annotations 
Log10 of count of 
publications in 
PubMed in which 
gene in which 
variant occurs is 
named in title or 
abstract PubMed 24.18 1 26.41 1 
  
Number of codons 
(in CDS) 
downstream of the 
codon where the 
insertion or 
deletion begins. C-terminal Remainder 3.43 17 4.42 8 
  
For insertions, this 
length is always 0.  
For deletions, this 
length is the 
number of deleted 
nucleotides.  Length of Reference Allele 4.19 14 2.44 13 
  
For insertions, this 
length is the 
number of inserted 
nucleotides.  For 
deletions, this 




The number of 
transcripts in the 
SNVBox database 
(from RefSeq and 
Ensembl) that 
cover the codon 
where the insertion 






factor PredBFactorF 10.34 6 2.11 17 
  Low stability PredStabilityL 4.97 12 2.25 15 
  
Solvent 
accessibility PredRSAE 6.49 10 2.03 18 
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Feature 

















charge RegCompKR 3.76 16 -1.1 33 
  Glutamine enriched RegCompQ 3.28 18 -0.19 25 
  Proline enriched RegCompP 3.98 15 4.84 7 
  Cysteine enriched RegCompC 4.48 13 -0.18 24 
  Glycine enriched RegCompG 3.01 19 1.45 20 
  Histidine enriched RegCompH -1.27 33 -0.42 28 
  Hydrophobic RegCompILVM 6.55 9 2.62 10 
  Aromatic RegCompWYF 11.57 3 2.29 14 
  
Negative formal 
charge RegCompDE 5.5 11 2.81 9 
  
Shannon entropy of 
amino acids 
surrounding 
position RegCompEntropy 14.28 2 7.94 4 
Protein-level 
annotations 
from UniProt Selenocysteine UniprotSECYS N/A N/A N/A N/A 
  Zinc finger UniprotZNFINGER 0.81 28 -0.84 30 
  
RNA-binding 
domain UniprotDOM_RNABD N/A N/A N/A N/A 
  
DNA-binding 
domain UniprotDNABIND 1.43 25 N/A N/A 
  in a protein domain   N/A N/A N/A N/A 
  
calcium-binding 
site UniprotCABIND N/A N/A N/A N/A 
  
post-translational 
modification site UniprotDOM_PostModRec N/A N/A N/A N/A 
  
transcription factor 




identified UniprotREGIONS 1.28 26 1.92 19 
  pro-peptide region UniprotPROPEP 1.01 27 -0.29 27 
  
site in a domain 
that binds to the 
cell membrane UniprotDOM_MMBRBD N/A N/A -1.43 35 
  
compositionally 
biased region UniprotCOMPBIAS 6.96 7 2.48 12 
  
any site annotation 
identified UniprotMODRES N/A N/A N/A N/A 
  
binding site of any 
kind UniprotBINDING N/A N/A N/A N/A 
  disulfide site UniprotDISULFID N/A N/A N/A N/A 
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Feature 










site of a domain 
that determines 
correct cellular 
localization UniprotDOM_LOC -0.01 32 -1.28 34 
  




or periplasm) UniprotSIGNAL 2.69 20 1.13 21 
  
transmembrane 
domain UniprotTRANSMEM 1.71 23 -0.19 25 
  
site in a domain 
involved in 
chromatin structure 




restion UniprotNPBIND N/A N/A 1.01 22 
  
site in an enzymatic 
domain responsible 
for any kind of 
post-translational 
modification UniprotDOM_PostModEnz 0.44 31 -0.17 23 
  repeat region UniprotREP 2.58 21 -0.93 31 
  metal-binding site UniprotMETAL N/A N/A N/A N/A 
  
site of a known 
functional motif UniprotMOTIF N/A N/A N/A N/A 
  
site in a protein-
protein interaction 
domain UniprotDOM_PPI 0.67 30 2.24 16 
  lipid-binding site UniprotLIMID N/A N/A N/A N/A 
  
site involved in 
enzymatic activity UniprotACTSITE N/A N/A N/A N/A 
  
carbohydrate-
binding site UniprotCARBOHYD N/A N/A -1.01 32 
 
Candidate features are divided into seven categories: DNA sequence conservation, 
DNA natural variation, gene-level annotations, transcript-level annotations, 
computational predictions of protein local structure, protein local regional sequence 
composition, amino acid residue conservation, and protein-level annotations from 
UniProtKB.  Each feature is described and labeled by the acronym used in the 
manuscript.  Feature importance Z-score for in-frame and out-of-frame classifiers 




Table S 2: VEST-indel Feature Importance Ranking 
 
Features 
Number In-frame Feature  
AUC 
ROC Included? Frameshift Feature  AUC ROC Included? 
1 PubMed 0.761 Yes PubMed 0.806 Yes 
2 RegCompEntropy 0.905 Yes AluSubPHC 0.872 Yes 
3 RegCompWYF 0.916 Yes ExonConservation 0.882 Yes 
4 ExonConservation 0.931 Yes RegCompEntropy 0.897 Yes 
5 AluSubPHC 0.937 Yes ExonSnpDensity 0.905 Yes 
6 PredBFactorF 0.948 Yes Transcripts 0.907 Yes 
7 UniprotCOMPBIAS 0.944 Yes RegCompP 0.901 Yes 
8 ExonSnpDensity 0.948 Yes C-terminal Remainder 0.905 Yes 
9 RegCompILVM 0.947 Yes RegCompDE 0.904 Yes 
10 PredRSAE 0.948 Yes RegCompILVM 0.906 Yes 
11 RegCompDE 0.950 Yes 
Length of Alternate 
Allele 0.911 Yes 
12 PredStabilityL 0.946 Yes UniprotCOMPBIAS 0.907 Yes 
13 RegCompC 0.949 Yes 
Length of Reference 
Allele 0.915 Yes 
14 Length of Reference Allele 0.948 Yes RegCompWYF 0.911 Yes 
15 RegCompP 0.946 Yes PredStabilityL 0.915 Yes 
16 RegCompKR 0.948 Yes UniprotDOM_PPI 0.917 Yes 
17 C-terminal Remainder 0.947 Yes PredBFactorF 0.915 No 
18 RegCompQ 0.948 Yes PredRSAE 0.913 No 
19 RegCompG 0.951 Yes UniprotREGIONS 0.914 No 
20 UniprotSIGNAL 0.950 Yes RegCompG 0.914 No 
21 UniprotREP 0.952 Yes UniprotSIGNAL 0.914 No 
22 Transcripts 0.949 Yes UniprotNPBIND 0.914 No 
23 PredSSH 0.952 Yes 
UniprotDOM_PostMo
dEnz 0.914 No 
24 UniprotTRANSMEM 0.948 No RegCompC 0.914 No 
25 UniprotDNABIND 0.948 No RegCompQ 0.914 No 
26 UniprotREGIONS 0.948 No UniprotTRANSMEM 0.914 No 
27 UniprotPROPEP 0.948 No UniprotPROPEP 0.914 No 
28 UniprotZNFINGER 0.948 No RegCompH 0.914 No 
29 Length of Alternate Allele 0.948 No PredSSH 0.914 No 
30 UniprotDOM_PPI 0.948 No UniprotZNFINGER 0.914 No 
 
AUC was calculated after the addition of the listed feature using an independent 
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Candidate features are divided into eight categories: DNA sequence conservation, 
DNA natural variation, gene-level annotations, transcript-level annotations, 
computational predictions of protein local structure, protein local regional sequence 
composition, amino acid residue conservation, amino acid conservation, and protein-
level annotations from UniProtKB.  Only features used in the method’s final classifier 
are included in the table. PROVEAN is not included in the table because it is a 
conservation based score and does not use features to make a classification.  
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Table S 5: Performance Comparison Restricted to Genes Containing at least one 
Pathogenic and one Benign Variant 
 
In-frame Sensitivity Specificity 
Balanced 
Accuracy 
VEST-indel 0.743 0.815 0.779 
SIFT-indel 0.680 0.770 0.725 
PROVEAN 0.786 0.630 0.708 
DDIG-in 0.627 0.870 0.749 
CADD 0.745 0.727 0.736 
        
Frameshift       
VEST-indel 0.536 0.796 0.666 
SIFT-indel 0.934 0.174 0.554 
DDIG-in 0.919 0.272 0.596 
CADD 0.982 0.013 0.498 
 
I compared the five tested methods on a difficult set of variants, limited to genes that 
contained at least one pathogenic and one benign variant (141 in-frame pathogenic and 




Table S 6: In-frame Boolean Meta-prediction Results 
 
Method Sensitivity Specificity 
Balanced 
Accuracy 
(VEST-indel AND PROVEAN) OR 
(CADD AND DDIG-in) 0.930 0.974 0.952 
(VEST-indel OR CADD) AND 
PROVEAN 0.947 0.955 0.951 
(VEST-indel OR CADD) AND 
(PROVEAN OR DDIG-in) 0.947 0.949 0.948 
VEST-indel OR (CADD AND 
PROVEAN AND DDIG-in 0.930 0.955 0.942 
VEST-indel OR (CADD AND 
DDIG-in) 0.930 0.949 0.939 
VEST-indel OR (DDIG-in AND 
CADD) 0.930 0.949 0.939 
VEST-indel OR (CADD AND 
PROVEAN) 0.947 0.929 0.938 
(VEST-indel OR DDIG-in) AND 
PROVEAN 0.930 0.942 0.936 
(VEST-indel AND PROVEAN) OR 
(SIFT-indel AND DDIG-in) 0.912 0.955 0.934 
(VEST-indel OR DDIG-in) AND 
(PROVEAN OR CADD) 0.930 0.936 0.933 
(VEST-indel OR CADD OR DDIG-
in) AND PROVEAN 0.947 0.917 0.932 
(VEST-indel OR CADD) AND 
(PROVEAN OR SIFT-indel) 0.965 0.897 0.931 
VEST-indel OR (SIFT-indel AND 
CADD AND DDIG-in 0.912 0.949 0.930 
(VEST-indel OR SIFT-indel OR 
CADD) AND PROVEAN 0.947 0.910 0.929 
VEST-indel OR (SIFT-indel AND 
PROVEAN AND CADD 0.912 0.942 0.927 
VEST-indel OR (SIFT-indel AND 
PROVEAN AND DDIG-in 0.912 0.942 0.927 
(VEST-indel AND PROVEAN) OR 
(SIFT-indel AND CADD) 0.930 0.923 0.926 
VEST-indel OR (DDIG-in AND 
PROVEAN) 0.930 0.917 0.923 
(VEST-indel OR DDIG-in) AND 
(PROVEAN OR SIFT-indel) 0.930 0.917 0.923 
(VEST-indel AND DDIG-in) OR 
(PROVEAN AND CADD) 0.877 0.968 0.923 
(VEST-indel AND SIFT-indel) OR 0.895 0.949 0.922 
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Method Sensitivity Specificity 
Balanced 
Accuracy 
(PROVEAN AND CADD) 
VEST-indel OR (SIFT-indel AND 
DDIG-in) 0.912 0.929 0.921 
(VEST-indel OR SIFT-indel) AND 
PROVEAN 0.912 0.923 0.918 
(VEST-indel AND PROVEAN) OR 
CADD 0.965 0.865 0.915 
VEST-indel OR (SIFT-indel AND 
CADD) 0.930 0.897 0.914 
(VEST-indel OR SIFT-indel OR 
DDIG-in) AND PROVEAN 0.930 0.897 0.914 
(VEST-indel OR DDIG-in) AND 
(CADD OR SIFT-indel) 0.877 0.949 0.913 
(VEST-indel OR SIFT-indel) AND 
(PROVEAN OR DDIG-in) 0.912 0.910 0.911 
(VEST-indel AND PROVEAN) OR 
DDIG-in 0.930 0.891 0.910 
(CADD AND PROVEAN) OR 
(SIFT-indel AND DDIG-in) 0.877 0.942 0.910 
(VEST-indel AND CADD) OR 
(PROVEAN AND DDIG-in) 0.860 0.955 0.907 
(CADD OR SIFT-indel) AND 
PROVEAN 0.895 0.917 0.906 
(SIFT-indel OR CADD) AND 
PROVEAN 0.895 0.917 0.906 
(VEST-indel AND CADD) OR 
(SIFT-indel AND DDIG-in) 0.842 0.968 0.905 
VEST-indel OR (SIFT-indel AND 
PROVEAN) 0.912 0.897 0.905 
(VEST-indel OR SIFT-indel) AND 
(PROVEAN OR CADD) 0.930 0.878 0.904 
(CADD OR DDIG-in) AND 
PROVEAN 0.877 0.929 0.903 
(VEST-indel OR PROVEAN) AND 
(CADD OR DDIG-in) 0.877 0.929 0.903 
VEST-indel OR CADD 0.965 0.840 0.902 
(VEST-indel AND SIFT-indel) OR 
(CADD AND DDIG-in) 0.825 0.974 0.899 
(CADD OR SIFT-indel) AND 
(PROVEAN OR DDIG-in) 0.895 0.904 0.899 
(VEST-indel OR PROVEAN) AND 
(SIFT-indel OR CADD) 0.895 0.904 0.899 
VEST-indel OR DDIG-in 0.930 0.865 0.898 
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Method Sensitivity Specificity 
Balanced 
Accuracy 
(VEST-indel AND CADD) OR 
(PROVEAN AND SIFT-indel) 0.860 0.929 0.895 
VEST-indel AND (CADD OR 
PROVEAN) 0.807 0.981 0.894 
VEST-indel AND (CADD OR 
PROVEAN OR DDIG-in 0.807 0.981 0.894 
VEST-indel AND (DDIG-in OR 
PROVEAN) 0.807 0.981 0.894 
VEST-indel AND PROVEAN 0.807 0.981 0.894 
(CADD OR SIFT-indel OR DDIG-
in) AND PROVEAN 0.895 0.891 0.893 
(VEST-indel AND SIFT-indel AND 
PROVEAN) OR CADD 0.912 0.872 0.892 
(VEST-indel OR SIFT-indel) AND 
(CADD OR DDIG-in) 0.860 0.917 0.888 
VEST-indel AND (SIFT-indel OR 
PROVEAN) 0.807 0.968 0.887 
VEST-indel AND (SIFT-indel OR 
PROVEAN OR CADD 0.807 0.968 0.887 
VEST-indel AND (SIFT-indel OR 
PROVEAN OR DDIG-in 0.807 0.968 0.887 
(CADD OR DDIG-in) AND 
(PROVEAN OR SIFT-indel) 0.895 0.878 0.886 
CADD OR (VEST-indel AND 
PROVEAN AND DDIG-in) 0.895 0.878 0.886 
(VEST-indel AND DDIG-in) OR 
CADD 0.895 0.878 0.886 
(VEST-indel AND SIFT-indel AND 
DDIG-in) OR CADD 0.895 0.878 0.886 
(VEST-indel AND SIFT-indel) OR 
CADD 0.912 0.859 0.886 
(VEST-indel AND SIFT-indel) OR 
(PROVEAN AND DDIG-in) 0.825 0.942 0.883 
(VEST-indel OR CADD) AND 
DDIG-in 0.772 0.994 0.883 
VEST-indel OR (CADD AND 
DDIG-in) 0.772 0.994 0.883 
(VEST-indel OR CADD) AND 
(SIFT-indel OR DDIG-in) 0.842 0.923 0.883 
(VEST-indel AND CADD AND 
PROVEAN) OR DDIG-in 0.860 0.904 0.882 
(VEST-indel AND CADD) OR 
DDIG-in 0.860 0.904 0.882 
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Method Sensitivity Specificity 
Balanced 
Accuracy 
VEST-indel 0.807 0.955 0.881 
CADD OR (SIFT-indel AND 
PROVEAN AND DDIG-in 0.895 0.865 0.880 
(CADD AND PROVEAN) OR 
DDIG-in 0.877 0.878 0.878 
DDIG-in OR (CADD AND 
PROVEAN) 0.877 0.878 0.878 
(CADD AND DDIG-in) OR 
(PROVEAN AND SIFT-indel) 0.825 0.929 0.877 
CADD OR (SIFT-indel AND 
DDIG-in) 0.895 0.859 0.877 
(SIFT-indel AND DDIG-in) OR 
CADD 0.895 0.859 0.877 
(VEST-indel AND DDIG-in) OR 
(CADD AND SIFT-indel) 0.807 0.942 0.875 
PROVEAN 0.947 0.801 0.874 
(VEST-indel AND CADD AND 
DDIG-in) OR PROVEAN 0.947 0.801 0.874 
(VEST-indel AND CADD) OR 
PROVEAN 0.947 0.801 0.874 
(VEST-indel AND DDIG-in) OR 
PROVEAN 0.947 0.801 0.874 
(VEST-indel AND SIFT-indel AND 
CADD) OR PROVEAN 0.947 0.801 0.874 
(VEST-indel AND SIFT-indel AND 
DDIG-in) OR PROVEAN 0.947 0.801 0.874 
CADD OR (SIFT-indel AND 
DDIG-in) 0.772 0.974 0.873 
DDIG-in AND (SIFT-indel OR 
CADD) 0.772 0.974 0.873 
(VEST-indel OR SIFT-indel OR 
CADD) AND DDIG-in 0.772 0.974 0.873 
(VEST-indel AND DDIG-in) OR 
(PROVEAN AND SIFT-indel) 0.807 0.936 0.871 
(CADD AND DDIG-in) OR 
PROVEAN 0.947 0.795 0.871 
(CADD AND SIFT-indel AND 
DDIG-in) OR PROVEAN 0.947 0.795 0.871 
CADD OR (SIFT-indel AND 
PROVEAN) 0.912 0.827 0.870 
(SIFT-indel AND DDIG-in) OR 
PROVEAN 0.947 0.788 0.868 
(VEST-indel AND SIFT-indel) OR 0.947 0.788 0.868 
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(SIFT-indel OR DDIG-in) AND 
PROVEAN 0.825 0.910 0.867 
CADD OR (DDIG-in AND 
PROVEAN) 0.895 0.840 0.867 
(DDIG-in AND PROVEAN) OR 
CADD 0.895 0.840 0.867 
DDIG-in AND PROVEAN 0.772 0.962 0.867 
(VEST-indel OR PROVEAN) AND 
DDIG-in 0.772 0.962 0.867 
VEST-indel AND (CADD OR 
DDIG-in) 0.737 0.994 0.865 
VEST-indel AND (DDIG-in OR 
CADD) 0.737 0.994 0.865 
VEST-indel AND (SIFT-indel OR 
CADD) 0.754 0.974 0.864 
VEST-indel AND (SIFT-indel OR 
CADD OR DDIG-in 0.754 0.974 0.864 
VEST-indel OR (SIFT-indel AND 
DDIG-in) 0.754 0.974 0.864 
(CADD AND SIFT-indel) OR 
(PROVEAN AND DDIG-in) 0.825 0.904 0.864 
(VEST-indel AND SIFT-indel AND 
PROVEAN) OR DDIG-in 0.825 0.904 0.864 
(CADD OR PROVEAN) AND 
DDIG-in 0.772 0.955 0.864 
DDIG-in AND (CADD OR 
PROVEAN) 0.772 0.955 0.864 
(VEST-indel OR CADD OR 
PROVEAN) AND DDIG-in 0.772 0.955 0.864 
(VEST-indel OR DDIG-in) AND 
SIFT-indel 0.772 0.955 0.864 
VEST-indel OR PROVEAN 0.947 0.776 0.862 
(VEST-indel OR PROVEAN) AND 
(SIFT-indel OR DDIG-in) 0.825 0.897 0.861 
(CADD AND SIFT-indel) OR 
PROVEAN 0.965 0.756 0.861 
(SIFT-indel AND CADD) OR 
PROVEAN 0.965 0.756 0.861 
VEST-indel OR CADD OR DDIG-
in 0.965 0.756 0.861 
VEST-indel OR DDIG-in OR 
CADD 0.965 0.756 0.861 
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Method Sensitivity Specificity 
Balanced 
Accuracy 
(CADD OR SIFT-indel OR 
PROVEAN) AND DDIG-in 0.772 0.949 0.860 
DDIG-in AND (SIFT-indel OR 
PROVEAN) 0.772 0.949 0.860 
(VEST-indel OR SIFT-indel OR 
PROVEAN) AND DDIG-in 0.772 0.949 0.860 
(VEST-indel AND SIFT-indel AND 
CADD) OR DDIG-in 0.807 0.910 0.859 
(VEST-indel AND SIFT-indel) OR 
DDIG-in 0.825 0.891 0.858 
(VEST-indel OR CADD) AND 
SIFT-indel 0.789 0.923 0.856 
(VEST-indel AND PROVEAN) OR 
SIFT-indel 0.965 0.744 0.854 
SIFT-indel AND PROVEAN 0.772 0.936 0.854 
(CADD OR PROVEAN) AND 
(SIFT-indel OR DDIG-in) 0.842 0.865 0.854 
SIFT-indel AND PROVEAN AND 
DDIG-in 0.719 0.987 0.853 
(CADD AND SIFT-indel AND 
PROVEAN) OR DDIG-in 0.807 0.897 0.852 
DDIG-in OR PROVEAN 0.947 0.750 0.849 
VEST-indel OR SIFT-indel 0.965 0.731 0.848 
(CADD OR DDIG-in) AND SIFT-
indel 0.772 0.923 0.848 
(DDIG-in OR CADD) AND SIFT-
indel 0.772 0.923 0.848 
(DDIG-in OR PROVEAN) AND 
SIFT-indel 0.772 0.923 0.848 
(VEST-indel OR PROVEAN) AND 
SIFT-indel 0.772 0.923 0.848 
SIFT-indel AND DDIG-in 0.719 0.974 0.847 
SIFT-indel AND (VEST-indel OR 
CADD OR DDIG-in) 0.789 0.904 0.847 
CADD OR DDIG-in 0.895 0.795 0.845 
DDIG-in OR CADD 0.895 0.795 0.845 
(VEST-indel OR DDIG-in) AND 
CADD 0.702 0.987 0.844 
CADD AND PROVEAN 0.719 0.968 0.844 
(VEST-indel OR PROVEAN) AND 
CADD 0.719 0.968 0.844 
(CADD AND PROVEAN) OR 0.947 0.737 0.842 
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(CADD AND SIFT-indel) OR 
DDIG-in 0.825 0.859 0.842 
DDIG-in OR (SIFT-indel AND 
CADD) 0.825 0.859 0.842 
DDIG-in OR (SIFT-indel AND 
PROVEAN) 0.825 0.859 0.842 
VEST-indel AND (SIFT-indel OR 
DDIG-in) 0.702 0.981 0.841 
DDIG-in 0.772 0.910 0.841 
SIFT-indel AND (VEST-indel OR 
PROVEAN OR DDIG-in) 0.772 0.910 0.841 
CADD AND (DDIG-in OR 
PROVEAN) 0.719 0.962 0.840 
CADD AND (VEST-indel OR 
PROVEAN OR DDIG-in) 0.719 0.962 0.840 
(DDIG-in OR PROVEAN) AND 
CADD 0.719 0.962 0.840 
(CADD OR PROVEAN) AND 
SIFT-indel 0.789 0.891 0.840 
CADD OR PROVEAN 0.965 0.712 0.838 
SIFT-indel AND (CADD OR 
PROVEAN OR DDIG-in) 0.789 0.885 0.837 
VEST-indel OR SIFT-indel OR 
CADD 1.000 0.673 0.837 
VEST-indel OR DDIG-in OR 
PROVEAN 0.947 0.724 0.836 
SIFT-indel AND (VEST-indel OR 
PROVEAN OR CADD) 0.789 0.878 0.834 
SIFT-indel OR (VEST-indel AND 
PROVEAN AND CADD) 0.912 0.750 0.831 
(VEST-indel AND CADD) OR 
SIFT-indel 0.912 0.750 0.831 
VEST-indel AND SIFT-indel AND 
PROVEAN 0.667 0.994 0.830 
CADD AND (SIFT-indel OR 
PROVEAN) 0.737 0.923 0.830 
CADD AND (SIFT-indel OR 
PROVEAN OR DDIG-in 0.737 0.923 0.830 
(VEST-indel OR SIFT-indel OR 
PROVEAN) AND CADD 0.737 0.923 0.830 
(VEST-indel OR SIFT-indel OR 
DDIG-in) AND CADD 0.719 0.936 0.828 
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Method Sensitivity Specificity 
Balanced 
Accuracy 
VEST-indel OR CADD OR 
PROVEAN 0.965 0.686 0.825 
VEST-indel AND DDIG-in 0.649 1.000 0.825 
VEST-indel AND DDIG-in AND 
PROVEAN 0.649 1.000 0.825 
VEST-indel OR SIFT-indel OR 
DDIG-in 0.982 0.667 0.825 
VEST-indel AND SIFT-indel 0.667 0.981 0.824 
CADD OR SIFT-indel 0.947 0.692 0.820 
SIFT-indel OR CADD 0.947 0.692 0.820 
(VEST-indel OR SIFT-indel) AND 
CADD 0.702 0.936 0.819 
VEST-indel OR (SIFT-indel AND 
CADD) 0.702 0.936 0.819 
(CADD AND DDIG-in) OR SIFT-
indel 0.877 0.756 0.817 
(DDIG-in AND CADD) OR SIFT-
indel 0.877 0.756 0.817 
SIFT-indel OR (CADD AND 
PROVEAN AND DDIG-in) 0.877 0.756 0.817 
CADD OR DDIG-in OR 
PROVEAN 0.965 0.667 0.816 
CADD OR PROVEAN OR DDIG-
in 0.965 0.667 0.816 
SIFT-indel OR PROVEAN 1.000 0.622 0.811 
SIFT-indel OR (VEST-indel AND 
CADD AND DDIG-in) 0.860 0.756 0.808 
SIFT-indel OR (VEST-indel AND 
PROVEAN AND DDIG-in) 0.860 0.756 0.808 
(VEST-indel AND DDIG-in) OR 
SIFT-indel 0.860 0.756 0.808 
CADD 0.737 0.878 0.808 
CADD AND DDIG-in AND 
PROVEAN 0.614 1.000 0.807 
CADD AND PROVEAN AND 
DDIG-in 0.614 1.000 0.807 
VEST-indel AND SIFT-indel AND 
DDIG-in 0.614 1.000 0.807 
VEST-indel AND SIFT-indel AND 
PROVEAN AND DDIG-in 0.614 1.000 0.807 
VEST-indel OR SIFT-indel OR 
CADD OR DDIG-in 1.000 0.609 0.804 
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Method Sensitivity Specificity 
Balanced 
Accuracy 
VEST-indel OR SIFT-indel OR 
PROVEAN 1.000 0.609 0.804 
CADD AND (SIFT-indel OR 
DDIG-in) 0.667 0.942 0.804 
(SIFT-indel OR DDIG-in) AND 
CADD 0.667 0.942 0.804 
(DDIG-in AND PROVEAN) OR 
SIFT-indel 0.877 0.731 0.804 
CADD AND DDIG-in 0.614 0.994 0.804 
DDIG-in AND CADD 0.614 0.994 0.804 
VEST-indel OR CADD OR 
PROVEAN OR DDIG-in 0.965 0.641 0.803 
CADD AND SIFT-indel AND 
PROVEAN 0.596 0.987 0.792 
SIFT-indel AND PROVEAN AND 
CADD 0.596 0.987 0.792 
SIFT-indel OR PROVEAN OR 
DDIG-in 1.000 0.583 0.792 
SIFT-indel 0.825 0.756 0.790 
CADD OR SIFT-indel OR 
PROVEAN 1.000 0.577 0.788 
SIFT-indel OR PROVEAN OR 
CADD 1.000 0.577 0.788 
CADD OR SIFT-indel OR DDIG-in 0.947 0.628 0.788 
SIFT-indel OR CADD OR DDIG-in 0.947 0.628 0.788 
VEST-indel AND CADD 0.579 0.994 0.786 
VEST-indel AND CADD AND 
PROVEAN 0.579 0.994 0.786 
VEST-indel OR SIFT-indel OR 
PROVEAN OR DDIG-in 1.000 0.571 0.785 
SIFT-indel OR DDIG-in 0.877 0.692 0.785 
VEST-indel OR SIFT-indel OR 
PROVEAN OR CADD 1.000 0.564 0.782 
CADD AND SIFT-indel AND 
PROVEAN AND DDIG-in 0.561 1.000 0.781 
CADD AND SIFT-indel 0.614 0.942 0.778 
SIFT-indel AND CADD 0.614 0.942 0.778 
CADD AND SIFT-indel AND 
DDIG-in 0.561 0.994 0.777 
SIFT-indel AND CADD AND 
DDIG-in 0.561 0.994 0.777 
CADD OR SIFT-indel OR 1.000 0.538 0.769 
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Method Sensitivity Specificity 
Balanced 
Accuracy 
PROVEAN OR DDIG-in 
VEST-indel AND CADD AND 
DDIG-in 0.491 1.000 0.746 
VEST-indel AND CADD AND 
PROVEAN AND DDIG-in 0.491 1.000 0.746 
VEST-indel AND DDIG-in AND 
CADD 0.491 1.000 0.746 
VEST-indel AND SIFT-indel AND 
CADD 0.491 1.000 0.746 
VEST-indel AND SIFT-indel AND 
PROVEAN AND CADD 0.491 1.000 0.746 
VEST-indel AND SIFT-indel AND 
CADD AND DDIG-in 0.456 1.000 0.728 
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Accuracy   
VEST-indel AND (SIFT-indel OR 
DDIG-in)  0.835   0.967   0.901  
VEST-indel  0.849   0.950   0.900  
VEST-indel AND (SIFT-indel OR 
CADD)  0.849   0.950   0.900  
VEST-indel AND (SIFT-indel OR 
CADD OR DDIG-in  0.849   0.950   0.900  
VEST-indel AND (DDIG-in OR 
CADD)  0.841   0.950   0.896  
VEST-indel AND CADD  0.833   0.950   0.891  
VEST-indel AND SIFT-indel  0.797   0.967   0.882  
VEST-indel AND SIFT-indel AND 
CADD  0.780   0.967   0.874  
VEST-indel OR (SIFT-indel AND 
DDIG-in)  0.946   0.783   0.864  
VEST-indel OR (SIFT-indel AND 
CADD AND DDIG-in  0.946   0.783   0.864  
(VEST-indel AND SIFT-indel) OR 
DDIG-in  0.941   0.783   0.862  
(VEST-indel AND SIFT-indel) OR 
(CADD AND DDIG-in)  0.941   0.783   0.862  
VEST-indel OR DDIG-in  0.956   0.767   0.861  
VEST-indel OR (DDIG-in AND 
CADD)  0.956   0.767   0.861  
(VEST-indel OR DDIG-in) AND 
(CADD OR SIFT-indel)  0.956   0.767   0.861  
(VEST-indel AND CADD) OR 
(SIFT-indel AND DDIG-in)  0.937   0.783   0.860  
(VEST-indel AND SIFT-indel AND 
CADD) OR DDIG-in  0.933   0.783   0.858  
(VEST-indel AND CADD) OR 
DDIG-in  0.948   0.767   0.857  
(VEST-indel OR DDIG-in) AND 
CADD  0.939   0.767   0.853  
(VEST-indel OR DDIG-in) AND 
SIFT-indel  0.893   0.800   0.847  
VEST-indel AND DDIG-in  0.638   0.983   0.811  
VEST-indel AND DDIG-in AND 
CADD  0.630   0.983   0.807  
VEST-indel AND SIFT-indel AND 
DDIG-in  0.600   0.983   0.792  








Accuracy   
CADD AND DDIG-in 
VEST-indel OR (SIFT-indel AND 
DDIG-in)  0.734   0.817   0.775  
DDIG-in  0.745   0.800   0.772  
(VEST-indel OR CADD) AND 
DDIG-in  0.745   0.800   0.772  
DDIG-in AND (SIFT-indel OR 
CADD)  0.745   0.800   0.772  
(VEST-indel OR SIFT-indel OR 
CADD) AND DDIG-in  0.745   0.800   0.772  
DDIG-in AND CADD  0.736   0.800   0.768  
SIFT-indel AND DDIG-in  0.697   0.817   0.757  
SIFT-indel AND CADD AND DDIG-
in  0.688   0.817   0.752  
VEST-indel OR (SIFT-indel AND 
CADD)  0.987   0.283   0.635  
(VEST-indel OR CADD) AND 
(SIFT-indel OR DDIG-in)  0.983   0.283   0.633  
(VEST-indel AND DDIG-in) OR 
(CADD AND SIFT-indel)  0.964   0.300   0.632  
(VEST-indel OR SIFT-indel) AND 
(CADD OR DDIG-in)  0.979   0.283   0.631  
DDIG-in OR (SIFT-indel AND 
CADD)  0.975   0.283   0.629  
(VEST-indel OR SIFT-indel) AND 
CADD  0.971   0.283   0.627  
(SIFT-indel OR DDIG-in) AND 
CADD  0.967   0.283   0.625  
(VEST-indel OR SIFT-indel OR 
DDIG-in) AND CADD  0.981   0.267   0.624  
(VEST-indel OR CADD) AND SIFT-
indel  0.935   0.300   0.618  
SIFT-indel AND (VEST-indel OR 
CADD OR DDIG-in)  0.935   0.300   0.618  
(DDIG-in OR CADD) AND SIFT-
indel  0.927   0.300   0.613  
(VEST-indel AND DDIG-in) OR 
SIFT-indel  0.973   0.250   0.611  
SIFT-indel OR (VEST-indel AND 
CADD AND DDIG-in)  0.973   0.250   0.611  
VEST-indel OR SIFT-indel  0.987   0.233   0.610  
(VEST-indel AND CADD) OR SIFT-








Accuracy   
SIFT-indel AND CADD  0.918   0.300   0.609  
SIFT-indel OR DDIG-in  0.983   0.233   0.608  
(DDIG-in AND CADD) OR SIFT-
indel  0.983   0.233   0.608  
VEST-indel OR SIFT-indel OR 
DDIG-in  0.998   0.217   0.607  
SIFT-indel  0.935   0.250   0.593  
VEST-indel OR CADD  1.000   0.050   0.525  
(VEST-indel AND SIFT-indel) OR 
CADD  1.000   0.050   0.525  
VEST-indel OR DDIG-in OR CADD  1.000   0.050   0.525  
DDIG-in OR CADD  0.992   0.050   0.521  
(VEST-indel AND DDIG-in) OR 
CADD  0.992   0.050   0.521  
(SIFT-indel AND DDIG-in) OR 
CADD  0.992   0.050   0.521  
(VEST-indel AND SIFT-indel AND 
DDIG-in) OR CADD  0.992   0.050   0.521  
CADD  0.983   0.050   0.517  
SIFT-indel OR CADD  1.000   -   0.000  0.500  
VEST-indel OR SIFT-indel OR 
CADD  1.000   -   0.000  0.500  
SIFT-indel OR CADD OR DDIG-in  1.000   -   0.000  0.500  
VEST-indel OR SIFT-indel OR 
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